<SEC-DOCUMENT>0001193125-21-349142.txt : 20211206
<SEC-HEADER>0001193125-21-349142.hdr.sgml : 20211206
<ACCEPTANCE-DATETIME>20211206172202
ACCESSION NUMBER:		0001193125-21-349142
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20211201
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20211206
DATE AS OF CHANGE:		20211206

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MEI Pharma, Inc.
		CENTRAL INDEX KEY:			0001262104
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				510407811
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50484
		FILM NUMBER:		211473942

	BUSINESS ADDRESS:	
		STREET 1:		11455 EL CAMINO REAL
		STREET 2:		SUITE 250
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		858-369-7100

	MAIL ADDRESS:	
		STREET 1:		11455 EL CAMINO REAL
		STREET 2:		SUITE 250
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MARSHALL EDWARDS INC
		DATE OF NAME CHANGE:	20030902
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d257552d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:meip="http://www.meipharma.com/20211201" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2021-12-01_to_2021-12-01">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2021-12-01_to_2021-12-01">0001262104</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="meip-20211201.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2021-12-01_to_2021-12-01"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-01</xbrli:startDate> <xbrli:endDate>2021-12-01</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2021-12-01_to_2021-12-01">8-K</ix:nonNumeric></span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of Earliest Event Reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2021-12-01_to_2021-12-01" format="ixt:datemonthdayyearen">December&#160;1, 2021</ix:nonNumeric></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2021-12-01_to_2021-12-01">MEI Pharma, Inc.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2021-12-01_to_2021-12-01" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2021-12-01_to_2021-12-01">000-50484</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2021-12-01_to_2021-12-01">51-0407811</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction of</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">incorporation or organization)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(I.R.S. Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2021-12-01_to_2021-12-01">11455 El Camino Real</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2021-12-01_to_2021-12-01">Suite 250</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2021-12-01_to_2021-12-01">San Diego</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2021-12-01_to_2021-12-01" format="ixt-sec:stateprovnameen">California</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2021-12-01_to_2021-12-01">92130</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Address of principal executive offices) (Zip Code)</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s telephone number, including area code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2021-12-01_to_2021-12-01">(858)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2021-12-01_to_2021-12-01">369-7100</ix:nonNumeric></span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<span style="font-style:italic">see</span> General Instruction A.2. below):</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2021-12-01_to_2021-12-01" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2021-12-01_to_2021-12-01" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2021-12-01_to_2021-12-01" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2021-12-01_to_2021-12-01" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Symbol</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2021-12-01_to_2021-12-01">Common stock, $0.00000002 par value</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2021-12-01_to_2021-12-01">MEIP</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2021-12-01_to_2021-12-01" format="ixt-sec:exchnameen">The NASDAQ Stock Market LLC</ix:nonNumeric></span></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;240.12b-2</span> of this chapter).</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2021-12-01_to_2021-12-01" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Emerging growth company</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top">&#9744;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to section 13(a) of the Exchange Act.</p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;8.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Other Events. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&#160;1, 2021 MEI Pharma, Inc. (the &#8220;<span style="text-decoration:underline">Company</span>&#8221;) entered into an underwriting agreement (the &#8220;<span style="text-decoration:underline">Underwriting</span> <span style="text-decoration:underline">Agreement</span>&#8221;) with Jefferies LLC, Stifel, Nicolaus&#160;&amp; Company, Incorporated and Wells Fargo Securities, LLC , as representatives of the several underwriters named therein (collectively, the &#8220;<span style="text-decoration:underline">Underwriters</span>&#8221;), relating to the issuance and sale of 20,125,000 shares (the &#8220;<span style="text-decoration:underline">Shares</span>&#8221;) of the Company&#8217;s common stock, par value $0.00000002 per share (&#8220;<span style="text-decoration:underline">Common Stock</span>&#8221;), at a public offering price of $2.60 per share, which includes 2,625,000 shares of Common Stock sold as a result of the exercise by the underwriters of an option to purchase additional shares of Common Stock, pursuant to that certain Underwriting Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The net proceeds to the Company from this offering are expected to be approximately $49,185,500, after deducting underwriting commissions and estimated offering expenses payable by the Company. The offering closed on December&#160;6, 2021. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The offering is being made pursuant to the Company&#8217;s effective registration statement on Form <span style="white-space:nowrap">S-3</span> (Registration Statement <span style="white-space:nowrap">No.&#160;333-238056)</span> previously filed with and declared effective by the Securities and Exchange Commission (the &#8220;<span style="text-decoration:underline">SEC</span>&#8221;) and a prospectus supplement and accompanying prospectus filed with the SEC. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Underwriting Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act of 1933, as amended, other obligations of the parties and termination provisions. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement, and may be subject to limitations agreed upon by the contracting parties. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing description of the Underwriting Agreement is not complete and is qualified in its entirety by reference to the full text of the Underwriting Agreement, a copy of which is filed as Exhibit 1.1 to this report and which is incorporated by reference herein. A copy of the opinion of Morgan, Lewis&#160;&amp; Bockius LLP relating to the legality of the issuance and sale of the Shares in the offering is attached as Exhibit 5.1 to this report. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&#160;1, 2021, the Company issued a press release announcing the pricing of the offering, a copy of which is attached as Exhibit 99.1 to this report and is incorporated herein by reference. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;9.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td style="width:93%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center">Exhibit<br />No.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">Description</td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;1.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d257552dex11.htm">Underwriting Agreement, dated as of December&#160;1, 2021, by and among the Company, Jefferies LLC, Stifel, Nicolaus&#160;&amp; Company, Incorporated, and Wells Fargo Securities, LLC, as representatives of the several underwriters named therein. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;5.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d257552dex51.htm">Opinion of Morgan, Lewis&#160;&amp; Bockius LLP regarding the validity of the offered shares. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d257552dex991.htm">Press release, dated December&#160;1, 2021. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURE </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0;margin-left:auto">


<tr>

<td style="width:7%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:92%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3">MEI PHARMA, INC.</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Daniel P. Gold</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Daniel P. Gold</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Chief Executive Officer</td></tr>
</table></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: December&#160;6, 2021 </p>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>d257552dex11.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-1.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 1.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>17,500,000 Shares of Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MEI Pharma, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>UNDERWRITING AGREEMENT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">December&nbsp;1, 2021 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">JEFFERIES LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">STIFEL, NICOLAUS&nbsp;&amp; COMPANY, INCORPORATED </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">WELLS FARGO
SECURITIES, LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As Representatives of the Several Underwriters </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Jefferies LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">520 Madison Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Stifel, Nicolaus&nbsp;&amp;
Company, Incorporated </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">787 7th Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11th Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10019 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Wells Fargo Securities, LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">500 West 33rd Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">14th Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10001 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Introductory.</B> MEI Pharma, Inc., a Delaware corporation (the &#147;<B>Company</B>&#148;), proposes to issue and sell to the several
underwriters named in <U>Schedule A</U> (the &#147;<B>Underwriters</B>&#148;) an aggregate of 17,500,000 shares of its common stock, par value $0.00000002 per share (the &#147;<B>Shares</B>&#148;). The 17,500,000 Shares to be sold by the Company are
called the &#147;<B>Firm Shares</B>.&#148; In addition, the Company has granted to the Underwriters an option to purchase up to an additional 2,625,000 Shares as provided in Section&nbsp;2. The additional 2,625,000 Shares to be sold by the Company
pursuant to such option are collectively called the &#147;<B>Optional Shares</B>.&#148; The Firm Shares and, if and to the extent such option is exercised, the Optional Shares are collectively called the &#147;<B>Offered Shares</B>.&#148; Jefferies
LLC (&#147;<B>Jefferies</B>&#148;), Stifel, Nicolaus&nbsp;&amp; Company, Incorporated (&#147;<B>Stifel</B>&#148;) and Wells Fargo Securities, LLC (&#147;<B>Wells Fargo</B>&#148;) have agreed to act as representatives of the several Underwriters (in
such capacity, the &#147;<B>Representatives</B>&#148;) in connection with the offering and sale of the Offered Shares. To the extent there are no additional underwriters listed on <U>Schedule A</U>, the term &#147;Representatives&#148; as used
herein shall mean you, as Underwriters, and the term &#147;Underwriters&#148; shall mean either the singular or the plural, as the context requires. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has prepared and filed with the Securities and Exchange Commission (the &#147;<B>Commission</B>&#148;) a shelf registration
statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3,</FONT> File <FONT STYLE="white-space:nowrap">No.&nbsp;333-238056,</FONT> including a base prospectus (the &#147;<B>Base Prospectus</B>&#148;) to be used in connection with the public
offering and sale of the Offered Shares. Such registration statement, as amended, including the financial statements, exhibits and schedules thereto, in the form in which it became effective under the Securities Act of 1933, as amended, and the
rules and regulations promulgated thereunder (collectively, the &#147;<B>Securities Act</B>&#148;), including all documents incorporated or deemed to be incorporated by reference therein and any information deemed to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
be a part thereof at the time of effectiveness pursuant to Rule&nbsp;430A or 430B under the Securities Act, is called the &#147;<B>Registration Statement</B>.&#148; Any registration statement
filed by the Company pursuant to Rule 462(b) under the Securities Act in connection with the offer and sale of the Offered Shares is called the &#147;<B>Rule 462(b) Registration Statement</B>,&#148; and from and after the date and time of filing of
any such Rule 462(b) Registration Statement the term &#147;Registration Statement&#148; shall include the Rule 462(b) Registration Statement. The preliminary prospectus supplement dated November&nbsp;30, 2021 describing the Offered Shares and the
offering thereof (the &#147;<B>Preliminary Prospectus Supplement</B>&#148;), together with the Base Prospectus, is called the &#147;<B>Preliminary Prospectus</B>,&#148; and the Preliminary Prospectus and any other prospectus supplement to the Base
Prospectus in preliminary form that describes the Offered Shares and the offering thereof and is used prior to the filing of the Prospectus (as defined below), together with the Base Prospectus, is called a &#147;<B>preliminary prospectus</B>.&#148;
As used herein, the term &#147;<B>Prospectus</B>&#148; shall mean the final prospectus supplement to the Base Prospectus that describes the Offered Shares and the offering thereof (the &#147;<B>Final Prospectus Supplement</B>&#148;), together with
the Base Prospectus, in the form first used by the Underwriters to confirm sales of the Offered Shares<B> </B>or in the form first made available to the Underwriters by the Company to meet requests of purchasers pursuant to Rule 173 under the
Securities Act. References herein to the Preliminary Prospectus, any preliminary prospectus and the Prospectus shall refer to both the prospectus supplement and the Base Prospectus components of such prospectus. As used herein, &#147;<B>Applicable
Time</B>&#148; is 5:00 p.m. (New York City time) on December&nbsp;1, 2021. As used herein, &#147;<B>free writing prospectus</B>&#148; has the meaning set forth in Rule 405 under the Securities Act, and &#147;<B>Time of Sale Prospectus</B>&#148;
means the Preliminary Prospectus, as amended or supplemented immediately prior to the Applicable Time, together with the free writing prospectuses, if any, identified in <U>Schedule B</U> hereto (any such free writing prospectus, a &#147;<B>Free
Writing Prospectus</B>&#148;), and the information set forth on <U>Schedule C</U> hereto. As used herein, <B>&#147;Road Show&#148;</B> means a &#147;road show&#148; (as defined in Rule 433 under the Securities Act) relating to the offering of the
Offered Shares contemplated hereby that is a &#147;written communication&#148; (as defined in Rule 405 under the Securities Act). As used herein, &#147;<B>Marketing Materials</B>&#148; means any materials or information provided to investors by, or
with the approval of, the Company in connection with the marketing of the offering of the Offered Shares, including any roadshow or investor presentations made to investors by the Company (whether in person or electronically). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All references in this Agreement to the Registration Statement, the Preliminary Prospectus, any preliminary prospectus, the Base Prospectus
and the Prospectus shall include the documents incorporated or deemed to be incorporated by reference therein. All references in this Agreement to financial statements and schedules and other information which are &#147;contained,&#148;
&#147;included&#148; or &#147;stated&#148; in, or &#147;part of&#148; the Registration Statement, the Rule 462(b) Registration Statement, the Preliminary Prospectus, any preliminary prospectus, the Base Prospectus, the Time of Sale Prospectus or the
Prospectus, and all other references of like import, shall be deemed to mean and include all such financial statements and schedules and other information which is or is deemed to be incorporated by reference in the Registration Statement, the Rule
462(b) Registration Statement, the Preliminary Prospectus, any preliminary prospectus, the Base Prospectus, the Time of Sale Prospectus or the Prospectus, as the case may be. All references in this Agreement to amendments or supplements to the
Registration Statement, the Preliminary Prospectus, any preliminary prospectus, the Base Prospectus, the Time of Sale Prospectus or the Prospectus shall be deemed to mean and include the filing of any document under the Securities Exchange Act of
1934, as amended, and the rules and regulations promulgated thereunder (collectively, the &#147;<B>Exchange Act</B>&#148;) that is or is deemed to be incorporated by reference in the Registration Statement, the Preliminary Prospectus, any
preliminary prospectus, the Base Prospectus, or the Prospectus, as the case may be. All references in this Agreement to the Registration Statement, the Preliminary Prospectus, any preliminary prospectus, the Base Prospectus or the Prospectus, any
amendments or supplements to any of the foregoing, or any free writing prospectus, shall include any copy thereof filed with the Commission pursuant to its Electronic Data Gathering, Analysis and Retrieval System (&#147;<B>EDGAR</B>&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that the Company has only one subsidiary, then all references herein to
&#147;subsidiaries&#148; of the Company shall be deemed to refer to such single subsidiary, <U>mutatis</U> <U>mutandis</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company
hereby confirms its agreements with the Underwriters as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;1.</B> <B>Representations and Warranties
</B><B>of the Company</B><B>.</B><B> </B>The Company hereby represents, warrants and covenants to each Underwriter, as of the date of this Agreement, as of the First Closing Date (as hereinafter defined) and as of each Option Closing Date (as
hereinafter defined), if any, as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B><I>Compliance with Registration Requirements</I></B><B>.</B> The Company meets
the requirements for use of Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act without reliance on General Instruction I.B.6 of Form <FONT STYLE="white-space:nowrap">S-3.</FONT> Each of the Registration Statement and any
amendment thereto has become effective under the Securities Act. No stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto has been issued under the Securities Act, no order preventing or
suspending the use of any preliminary prospectus or the Prospectus has been issued and no proceedings for any of those purposes have been instituted or are pending or, to the Company&#146;s knowledge, contemplated. The Company has complied with each
request (if any) from the Commission for additional information. Each of the Registration Statement and any post-effective amendment thereto, at the time it became effective, complied in all material respects with the requirements of the Securities
Act and the Securities Act Regulations. Each preliminary prospectus, the Prospectus and any amendment or supplement thereto, at the time each was filed with the Commission, complied in all material respects with the requirements of the Securities
Act and the Securities Act Regulations. Each preliminary prospectus delivered to the Underwriters for use in connection with this offering and the Prospectus was or will be identical to the electronically transmitted copies thereof filed with the
Commission pursuant to EDGAR, except to the extent permitted by Regulation <FONT STYLE="white-space:nowrap">S-T.</FONT> The documents incorporated or deemed to be incorporated by reference in the Registration Statement and the Prospectus, when they
became effective or at the time they were or hereafter are filed with the Commission, complied and will comply in all material respects with the requirements of the Exchange Act and the rules and regulations of the Commission under the Exchange Act
(the &#147;<B>Exchange Act Regulations</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B><I>Disclosure</I></B><B>.</B> Neither the Registration Statement nor any
amendment thereto, at its effective time, at the First Closing Date or at any Option Closing Date, contained, contains or will contain an untrue statement of a material fact or omitted, omits or will omit to state a material fact required to be
stated therein or necessary to make the statements therein not misleading. As of the Applicable Time, the Time of Sale Prospectus did not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the
statements therein, in the light of the circumstances under which they were made, not misleading. Neither the Prospectus nor any amendment or supplement thereto (including any prospectus wrapper), as of its issue date, at the time of any filing with
the Commission pursuant to Rule 424(b), at the First Closing Date or at any Option Closing Date, included, includes or will include an untrue statement of a material fact or omitted, omits or will omit to state a material fact necessary in order to
make the statements therein, in the light of the circumstances under which they were made, not misleading. The documents incorporated or deemed to be incorporated by reference in the Registration Statement, the Time of Sale Prospectus and the
Prospectus, at the time the Registration Statement became effective or when such documents incorporated by reference were filed with the Commission, as the case may be, when read together with the other information in the Registration Statement, the
Time of Sale Prospectus or the Prospectus, as the case may be, did not and will not include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not
misleading. The representations and warranties in this subsection shall not apply to statements in or omissions from the Registration Statement (or any amendment thereto), the Time of Sale Prospectus or the Prospectus (or any amendment or supplement
thereto) made in reliance upon and in conformity with written information furnished to the Company by any Underwriter through the Representatives expressly for use therein. For purposes of this Agreement, the only information so furnished shall be
the information described in Section&nbsp;9(b) hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B><I>Free Writing Prospectuses; Road Show</I></B><B>.</B> No Free Writing
Prospectus conflicts or will conflict with the information contained in the Registration Statement or the Prospectus, including any document incorporated by reference therein, and any preliminary or other prospectus deemed to be a part thereof that
has not been superseded or modified Except for the Free Writing Prospectuses, if any, identified in <U>Schedule B</U>, and electronic road shows, if any, furnished to you before first use, the Company has not prepared, used or referred to, and will
not, without your prior written consent, prepare, use or refer to, any free writing prospectus. Each Road Show, when considered together with the Time of Sale Prospectus, did not, as of the Applicable Time, contain any untrue statement of a material
fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B><I>Distribution of Offering Material By the Company</I></B><B>.</B> Prior to the later of (i)&nbsp;the expiration or termination
of the option granted to the several Underwriters in Section&nbsp;2, and (ii)&nbsp;the completion of the Underwriters&#146; distribution of the Offered Shares<B>,</B> the Company has not distributed and will not distribute any offering material in
connection with the offering and sale of the Offered Shares other than the Registration Statement, the Time of Sale Prospectus, the Prospectus or any Free Writing Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B><I>No Material Adverse Change</I></B><B>.</B> Except as otherwise stated therein, since the respective dates as of which
information is given in the Registration Statement, the Time of Sale Prospectus or the Prospectus, (A)&nbsp;there has been no material adverse change in the condition, financial or otherwise, or in the business affairs or business prospects of the
Company and its subsidiaries considered as one enterprise, whether or not arising in the ordinary course of business (a &#147;<B>Material Adverse Change</B>&#148;), (B) there have been no transactions entered into by the Company or any of its
subsidiaries, other than those in the ordinary course of business, which are material with respect to the Company and its subsidiaries considered as one enterprise, and (C)&nbsp;there has been no dividend or distribution of any kind declared, paid
or made by the Company on any class of its capital stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> <B><I>Independent Accountants</I></B><B>.</B> The accountants who
certified the financial statements and supporting schedules included in the Registration Statement, the Time of Sale Prospectus and the Prospectus are independent public accountants as required by the Securities Act, the Securities Act Regulations,
the Exchange Act, the Exchange Act Regulations and the Public Accounting Oversight Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> <B><I>Financial
Statements</I></B><B>.</B> The financial statements included or incorporated by reference in the Registration Statement, the Time of Sale Prospectus and the Prospectus, together with the related schedules and notes, present fairly the financial
position of the Company and its consolidated subsidiaries at the dates indicated and the statement of operations, stockholders&#146; equity and cash flows of the Company and its consolidated subsidiaries for the periods specified; said financial
statements have been prepared in conformity with U.S. generally accepted accounting principles (&#147;<B>GAAP</B>&#148;) applied on a consistent basis throughout the periods involved. The supporting schedules, if any, present fairly in accordance
with GAAP the information required to be stated therein. The selected financial data and the summary financial information included in the Registration Statement, the Time of Sale Prospectus and the Prospectus present fairly the information shown
therein and have been compiled on a basis consistent with that of the audited financial statements included therein. Except as included therein, no historical or pro forma financial statements or supporting schedules are required to be included or
incorporated by reference in the Registration Statement, the Time of Sale Prospectus or the Prospectus under the Securities Act or the Securities Act Regulations. All disclosures contained in the Registration Statement, the Time of Sale
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Prospectus or the Prospectus, or incorporated by reference therein, regarding <FONT STYLE="white-space:nowrap">&#147;non-GAAP</FONT> financial measures&#148; (as such term is defined by the rules
and regulations of the Commission) comply with Regulation G of the Exchange Act and Item 10 of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> of the Securities Act, to the extent applicable. The interactive data in eXtensible Business
Reporting Language incorporated by reference in the Registration Statement, the Time of Sale Prospectus and the Prospectus fairly presents the information called for in all material respects and has been prepared in accordance with the
Commission&#146;s rules and guidelines applicable thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> <B><I>Disclosure Controls and Procedures; Deficiencies in or
Changes to Internal Control Over Financial Reporting</I></B><B>.</B> The Company and each of its subsidiaries maintain effective internal control over financial reporting (as defined under Rule <FONT STYLE="white-space:nowrap">13-a15</FONT> and <FONT
STYLE="white-space:nowrap">15d-15</FONT> under the Exchange Act Regulations) and a system of internal accounting controls sufficient to provide reasonable assurances that (A)&nbsp;transactions are executed in accordance with management&#146;s
general or specific authorization; (B)&nbsp;transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain accountability for assets; (C)&nbsp;access to assets is permitted only in
accordance with management&#146;s general or specific authorization; (D)&nbsp;the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences; and
(E)&nbsp;the interactive data in eXtensible Business Reporting Language incorporated by reference in the Registration Statement, the Time of Sale Prospectus and the Prospectus fairly presents the information called for in all material respects and
is prepared in accordance with the Commission&#146;s rules and guidelines applicable thereto. Except as described in the Registration Statement, the Time of Sale Prospectus and the Prospectus, since the end of the Company&#146;s most recent audited
fiscal year, there has been (1)&nbsp;no material weakness in the Company&#146;s internal control over financial reporting (whether or not remediated) and (2)&nbsp;no change in the Company&#146;s internal control over financial reporting that has
materially affected, or is reasonably likely to materially affect, the Company&#146;s internal control over financial reporting. The Company and each of its subsidiaries maintain an effective system of disclosure controls and procedures (as defined
in Rule <FONT STYLE="white-space:nowrap">13a-15</FONT> and Rule <FONT STYLE="white-space:nowrap">15d-15</FONT> under the Exchange Act Regulations) that are designed to ensure that information required to be disclosed by the Company in the reports
that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission&#146;s rules and forms, and is accumulated and communicated to the Company&#146;s management,
including its principal executive officer or officers and principal financial officer or officers, as appropriate, to allow timely decisions regarding disclosure. Neither the Company&#146;s board of directors nor the audit committee has been
informed, nor is any director of the Company or the Company aware, of (i)&nbsp;during the past 36 months, any &#147;significant deficiencies&#148; or &#147;material weaknesses&#148; (each as defined by the Public Company Accounting Oversight Board)
in the design or operation of the Company&#146;s internal controls that could adversely affect the Company&#146;s ability to record, process, summarize and report financial data, required to be disclosed by the Company in reports filed with the
Commission that were not so disclosed; or (ii)&nbsp;any fraud, whether or not material, that involves management or other employees of the Company who have a significant role in the Company&#146;s internal controls. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B><I>Good Standing of the Company</I></B><B>.</B> The Company has been duly organized and is validly existing as a corporation in
good standing under the laws of the State of Delaware and has corporate power and authority to own, lease and operate its properties and to conduct its business as described in the Registration Statement, the Time of Sale Prospectus and the
Prospectus and to enter into and perform its obligations under this Agreement; and the Company is duly qualified as a foreign corporation to transact business and is in good standing in each other jurisdiction in which such qualification is
required, whether by reason of the ownership or leasing of property or the conduct of business, except where the failure so to qualify or to be in good standing would not result in a material adverse effect on the condition, financial or otherwise,
or in the business affairs or business prospects of the Company and its subsidiaries considered as one enterprise (a &#147;<B>Material Adverse Effect</B>&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j)</B> <B><I>Authorization of Agreement</I></B><B>.</B> This Agreement has been duly
authorized, executed and delivered by the Company. All corporate actions (including those of stockholders) necessary for the Company to consummate the transactions contemplated in this Agreement have been obtained and are in effect. The approval of
the Company&#146;s stockholders is not required under the rules and regulations of any trading market for the Company to issue and deliver to the Underwriters the Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k)</B> <B><I>Authorization and Description of Securities</I></B><B>.</B> The Securities to be purchased by the Underwriters from the
Company have been duly authorized for issuance and sale to the Underwriters pursuant to this Agreement and, when issued and delivered by the Company pursuant to this Agreement against payment of the consideration set forth herein, will be validly
issued and fully paid and <FONT STYLE="white-space:nowrap">non-assessable;</FONT> and the issuance of the Securities is not subject to the preemptive or other similar rights of any securityholder of the Company, except for any such rights which have
been satisfied or waived. The Common Stock conforms in all material respects to all statements relating thereto contained in the Registration Statement, the Time of Sale Prospectus and the Prospectus and such description conforms in all material
respects to the rights set forth in the instruments defining the same. No holder of Securities will be subject to personal liability solely by reason of being such a holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(l)</B> <B><I>Registration Rights</I></B><B>.</B> There are no persons with registration rights or other similar rights to have any
securities registered for sale pursuant to the Registration Statement or otherwise registered for sale or sold by the Company under the Securities Act pursuant to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(m)</B> <B><I>Absence of Violations, Defaults and Conflicts</I></B>. Neither the Company nor any of its subsidiaries is (A)&nbsp;in
violation of its charter, <FONT STYLE="white-space:nowrap">by-laws</FONT> or similar organizational document, (B)&nbsp;in default in the performance or observance of any obligation, agreement, covenant or condition contained in any contract,
indenture, mortgage, deed of trust, loan or credit agreement, note, lease or other agreement or instrument to which the Company or any of its subsidiaries is a party or by which it or any of them may be bound or to which any of the properties or
assets of the Company or any subsidiary is subject (collectively, &#147;<B>Agreements and Instruments</B>&#148;), except for such defaults that would not, singly or in the aggregate, result in a Material Adverse Effect, or (C)&nbsp;in violation of
any law, statute, rule, regulation, judgment, order, writ or decree of any arbitrator, court, governmental body, regulatory body, administrative agency or other authority, body or agency having jurisdiction over the Company or any of its
subsidiaries or any of their respective properties, assets or operations (each, a &#147;<B>Governmental Entity</B>&#148;), except for such violations that would not, singly or in the aggregate, result in a Material Adverse Effect. The execution,
delivery and performance of this Agreement and the consummation of the transactions contemplated herein and in the Registration Statement, the Time of Sale Prospectus and the Prospectus (including the issuance and sale of the Securities and the use
of the proceeds from the sale of the Securities as described therein under the caption &#147;<B><I>Use of Proceeds</I></B>&#148;) and compliance by the Company with its obligations hereunder have been duly authorized by all necessary corporate
action and do not and will not, whether with or without the giving of notice or passage of time or both, conflict with or constitute a breach of, or default or Repayment Event (as defined below) under, or result in the creation or imposition of any
lien, charge or encumbrance upon any properties or assets of the Company or any subsidiary pursuant to, the Agreements and Instruments (except for such conflicts, breaches, defaults or Repayment Events or liens, charges or encumbrances that would
not, singly or in the aggregate, result in a Material Adverse Effect), nor will such action result in any violation of (i)&nbsp;the provisions of the charter, <FONT STYLE="white-space:nowrap">by-laws</FONT> or similar organizational document of the
Company or any of its subsidiaries or (ii)&nbsp;any law, statute, rule, regulation, judgment, order, writ or decree of any Governmental Entity, except for such violations described in (ii)&nbsp;that would not, singly or in the aggregate, result in a
Material Adverse Effect. As used herein, a &#147;<B>Repayment Event</B>&#148; means any event or condition which gives the holder of any note, debenture or other evidence of indebtedness (or any person acting on such holder&#146;s behalf) the right
to require the repurchase, redemption or repayment of all or a portion of such indebtedness by the Company or any of its subsidiaries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(n)</B> <B><I>Subsidiaries</I></B><B>.</B> As of the date of this Agreement, the Company
does not own or control, directly or indirectly, any corporation, association or other entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(o)</B> <B><I>Capitalization and Other
Capital Stock Matters</I></B><B>.</B> The authorized, issued and outstanding shares of capital stock of the Company are as set forth in the Registration Statement, the Time of Sale Prospectus and the Prospectus (except for subsequent issuances, if
any, pursuant to this Agreement, pursuant to reservations, agreements or employee benefit plans referred to in the Registration Statement, the Time of Sale Prospectus and the Prospectus or pursuant to the exercise of convertible securities or
options referred to in the Registration Statement, the Time of Sale Prospectus and the Prospectus). The outstanding shares of capital stock of the Company have been duly authorized and validly issued and are fully paid and <FONT
STYLE="white-space:nowrap">non-assessable.</FONT> None of the outstanding shares of capital stock of the Company were issued in violation of the preemptive or other similar rights of any securityholder of the Company. Except as described or
contemplated in the Registration Statement, the Time of Sale Prospectus and the Prospectus, there are no options, warrants, agreements, contracts or other rights in existence to purchase or acquire from the Company any shares of the capital stock of
the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(p)</B> <B><I>Stock Exchange Listing</I></B><B>.</B> The Common Stock of the Company is registered pursuant to
Section&nbsp;12(b) of the Exchange Act and is listed on the NASDAQ Capital Market (&#147;<B>NASDAQ</B>&#148;) under the ticker symbol &#147;MEIP.&#148; The Company has taken no action designed to, or likely to have the effect of, terminating the
registration of the Common Stock under the Exchange Act or delisting the Common Stock from the NASDAQ Capital Market nor has the Company received any notice that it is not in compliance with the listing or maintenance requirements of the NASDAQ
Capital Market. The Company believes that it is, and it will in the foreseeable future continue to be, in material compliance with all such listing and maintenance requirements. A registration statement relating to the Common Stock on Form <FONT
STYLE="white-space:nowrap">8-A</FONT> or other applicable form under the Exchange Act has become effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(q)</B> <B><I>Compliance
with Laws</I></B><B><I>.</I></B> The Company and its subsidiaries have been and are in compliance with all applicable laws, rules and regulations, except where failure to be so in compliance could not be expected, individually or in the aggregate,
to have a Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(r)</B> <B><I>Absence of Labor Dispute.</I></B> No labor dispute with the employees of the Company
or any of its subsidiaries exists or, to the knowledge of the Company, is imminent, and the Company is not aware of any existing or imminent labor disturbance by the employees of any of its or any subsidiary&#146;s principal suppliers,
manufacturers, customers or contractors, which, in either case, would result in a Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(s)</B> <B><I>No Material
Actions or Proceedings</I></B><B>.</B> Except as disclosed in the Registration Statement, the Time of Sale Prospectus and the Prospectus, there is no action, suit, proceeding, inquiry or investigation before or brought by any Governmental Entity now
pending or, to the knowledge of the Company, threatened, against or affecting the Company or any of its subsidiaries, which could reasonably be expected to result in a Material Adverse Effect, or which could reasonably be expected to materially and
adversely affect their respective properties or assets or the consummation of the transactions contemplated in this Agreement or the performance by the Company of its obligations hereunder; and the aggregate of all pending legal or governmental
proceedings to which the Company or any such subsidiary is a party or of which any of their respective properties or assets is the subject which are not described in the Registration Statement, the Time of Sale Prospectus and the Prospectus,
including ordinary routine litigation incidental to the business, could not result in a Material Adverse Effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(t)</B> <B><I>Intellectual Property Rights</I></B><B>.</B> The Company and its
subsidiaries own or possess, or can acquire on reasonable terms, adequate patents, patent rights, licenses, inventions, copyrights, know how (including trade secrets and other unpatented and/or unpatentable proprietary or confidential information,
systems or procedures), trademarks, service marks, trade names or other intellectual property (collectively, &#147;<B>Intellectual Property</B>&#148;) necessary to carry on the business now operated by them except as such failure to own, possess, or
acquire such rights would not be reasonably expected to have a Material Adverse Effect, and neither the Company nor any of its subsidiaries has received any notice or is otherwise aware of any infringement of or conflict with asserted rights of
others with respect to any Intellectual Property or of any facts or circumstances which would render any Intellectual Property invalid or inadequate to protect the interest of the Company or any of its subsidiaries therein, and which infringement or
conflict (if the subject of any unfavorable decision, ruling or finding) or invalidity or inadequacy, singly or in the aggregate, would result in a Material Adverse Effect. Except as set forth in the Registration Statement, the Time of Sale
Prospectus and the Prospectus, the Company has not granted rights to develop, manufacture, produce, assemble, distribute, license, market or sell its products to any other person, and the Company is not bound by any agreement that affects the
Company&#146;s exclusive right to develop, manufacture, produce, assemble, distribute, license, market or sell its products. To the Company&#146;s knowledge, no employee of the Company is in or has ever been in violation of any term of any
employment contract, patent disclosure agreement, invention assignment agreement, <FONT STYLE="white-space:nowrap">non-competition</FONT> agreement, <FONT STYLE="white-space:nowrap">non-solicitation</FONT> agreement, nondisclosure agreement or any
restrictive covenant to or with a former employer where the basis of such violation relates to such employee&#146;s employment with the Company or actions undertaken by the employee while employed with the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(u)</B> <B><I>All Necessary Permits, etc</I></B><B>.</B> The Company and its subsidiaries possess such permits, licenses, approvals,
consents and other authorizations (collectively, &#147;<B>Governmental Licenses</B>&#148;) issued by the appropriate Governmental Entities necessary to conduct the business now operated by them, including without limitation the United States Food
and Drug Administration (&#147;<B>FDA</B>&#148;) or any other federal, state or foreign agencies or bodies engaged in the regulation of pharmaceuticals, animal or human clinical studies or biohazardous substances, except where the failure so to
possess would not, singly or in the aggregate, result in a Material Adverse Effect. The Company and its subsidiaries are in compliance with the terms and conditions of all Governmental Licenses, except where the failure so to comply would not,
singly or in the aggregate, result in a Material Adverse Effect. All of the Governmental Licenses are valid and in full force and effect, except when the invalidity of such Governmental Licenses or the failure of such Governmental Licenses to be in
full force and effect would not, singly or in the aggregate, result in a Material Adverse Effect. Neither the Company nor any of its subsidiaries has received any notice of proceedings relating to the revocation or modification of any Governmental
Licenses which, singly or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would reasonably be expected to result in a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> <B><I>FDA Regulations</I></B><B>.</B> The Company has operated and currently is in compliance with the United States Federal Food,
Drug, and Cosmetic Act, as amended, and all applicable rules and regulations of the FDA and other federal, state, local and foreign governmental bodies exercising comparable authority, except where the failure to so operate or be in compliance would
not reasonably be expected to have a Material Adverse Effect. The clinical studies conducted by or, to the Company&#146;s knowledge, on behalf of the Company that are described in the Registration Statement and the Prospectus were, and, if still
pending, are being, conducted in all material respects in accordance with the protocols submitted to the FDA and all applicable laws and regulations; preclinical studies conducted by or, to the Company&#146;s knowledge, on behalf of the Company or
any of its subsidiaries that are described in the Registration Statement and the Prospectus were, and, if still pending, are being, conducted in all material respects in accordance with experimental protocols, procedures and controls; the
descriptions of the tests and preclinical and clinical studies, and results thereof, conducted by or, to the Company&#146;s knowledge, on behalf of the Company contained in the Registration Statement and the Prospectus are accurate and complete in
all material respects; and the Company is not aware of any other trials or studies, the results of which reasonably call into question the results described or referred to in the Registration Statement and the Prospectus; and the Company has not
received any written notice or correspondence from the FDA or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any foreign, state or local governmental body exercising comparable authority requiring the termination, suspension, or clinical hold of any preclinical or clinical studies, or such written
notice or correspondence from any Institutional Review Board or comparable authority requiring the termination or suspension of a clinical study, conducted by or on behalf of the Company, which termination, suspension, or clinical hold would
reasonably be expected to have a Material Adverse Effect. None of the Company, its subsidiaries, or their respective business operations, except as would not reasonably be expected to result in a Material Adverse Effect, is in violation of the
Health Insurance Portability and Accountability Act of 1996, as amended (Pub. L. <FONT STYLE="white-space:nowrap">No.&nbsp;104-191)</FONT> and the Health Information Technology for Economic and Clinical Health Act of 2009, as amended, and the
regulations promulgated thereunder and comparable state privacy and security laws. The Company has not received written notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any
governmental authority alleging that any product candidate, operation or activity is in material violation of any permit or Food, Drug and Cosmetic Act provision and has no knowledge that any such governmental authority is considering any such
claim, litigation, arbitration, action, suit, investigation or proceeding; and the Company has not received notice, either verbally or in writing, that any governmental authority has taken, is taking or intends to take action to limit, suspend,
modify or revoke any material permits and has no knowledge that any such governmental authority is considering such action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(w)</B>
<B><I>Title to Properties</I></B><B>.</B> The Company and its subsidiaries have good and marketable title to all real property owned by them and good title to all other properties owned by them, in each case, free and clear of all mortgages,
pledges, liens, security interests, claims, restrictions or encumbrances of any kind except such as (A)&nbsp;are described in the Registration Statement, the Time of Sale Prospectus and the Prospectus or (B)&nbsp;do not, singly or in the aggregate,
materially affect the value of such property and do not interfere with the use made and proposed to be made of such property by the Company or any of its subsidiaries; and all of the leases and subleases material to the business of the Company and
its subsidiaries, considered as one enterprise, and under which the Company or any of its subsidiaries holds properties described in the Registration Statement, the Time of Sale Prospectus or the Prospectus, are in full force and effect, and neither
the Company nor any such subsidiary has any notice of any material claim of any sort that has been asserted by anyone adverse to the rights of the Company or any subsidiary under any of the leases or subleases mentioned above, or affecting or
questioning the rights of the Company or such subsidiary to the continued possession of the leased or subleased premises under any such lease or sublease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(x)</B> <B><I>Insurance</I></B><B>.</B> The Company and its subsidiaries carry or are entitled to the benefits of insurance, with
financially sound and reputable insurers, in such amounts and covering such risks as is generally maintained by companies of established repute engaged in the same or similar business, and all such insurance is in full force and effect. The Company
has no reason to believe that it or any of its subsidiaries will not be able (A)&nbsp;to renew its existing insurance coverage as and when such policies expire or (B)&nbsp;to obtain comparable coverage from similar institutions as may be necessary
or appropriate to conduct its business as now conducted and at a cost that would not result in a Material Adverse Change. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(y)</B>
<B><I>Compliance with Environmental Laws</I></B><B>.</B> Except as described in the Registration Statement, the Time of Sale Prospectus and the Prospectus or would not, singly or in the aggregate, result in a Material Adverse Effect,
(A)&nbsp;neither the Company nor any of its subsidiaries is in violation of any federal, state, local or foreign statute, law, rule, regulation, ordinance, code, policy or rule of common law or any judicial or administrative interpretation thereof,
including any judicial or administrative order, consent, decree or judgment, relating to pollution or protection of human health, the environment (including, without limitation, ambient air, surface water, groundwater, land surface or subsurface
strata) or wildlife, including, without limitation, laws and regulations relating to the release or threatened release of chemicals, pollutants, contaminants, wastes, toxic substances, hazardous substances, petroleum or petroleum products,
asbestos-containing materials or mold (collectively, &#147;<B>Hazardous Materials</B>&#148;) or to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials (collectively, &#147;<B>Environmental Laws</B>&#148;), (B) the Company
and its subsidiaries have all permits, authorizations and approvals required under any applicable Environmental Laws and are each in compliance with their requirements, (C)&nbsp;there are no pending or threatened administrative, regulatory or
judicial actions, suits, demands, demand letters, claims, liens, notices of noncompliance or violation, investigation or proceedings relating to any Environmental Law against the Company or any of its subsidiaries and (D)&nbsp;there are no events or
circumstances that would reasonably be expected to form the basis of an order for <FONT STYLE="white-space:nowrap">clean-up</FONT> or remediation, or an action, suit or proceeding by any private party or Governmental Entity, against or affecting the
Company or any of its subsidiaries relating to Hazardous Materials or any Environmental Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(z)</B> <B><I>Compliance with
Occupational Safety Laws</I></B><B>.</B> The Company (i)&nbsp;is in compliance, in all material respects, with any and all applicable foreign, federal, state and local laws, rules, regulations, treaties, statutes and codes promulgated by any and all
governmental authorities (including pursuant to the Occupational Health and Safety Act) relating to the protection of human health and safety in the workplace (&#147;<B>Occupational Laws</B>&#148;); (ii) has received all material Permits required of
it under applicable Occupational Laws to conduct its business as currently conducted; and (iii)&nbsp;is in compliance, in all material respects, with all terms and conditions of such Permit. No action, proceeding, revocation proceeding, writ,
injunction or claim is pending or, to the Company&#146;s knowledge, threatened against the Company relating to Occupational Laws that would reasonably be expected to have a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(aa)</B> <B><I>Compliance with the Sarbanes-Oxley Act</I></B><B>.</B> There is and has been no failure on the part of the Company or any of
the Company&#146;s directors or officers, in their capacities as such, to comply in all material respects with any provision of the Sarbanes-Oxley Act of 2002, as amended, and the rules and regulations promulgated in connection therewith, including
Section&nbsp;402 related to loans and Sections 302 and 906 related to certifications. No relationship, direct or indirect, exists between or among the Company, on the one hand, and the directors or officers or, to the knowledge of the Company,
stockholders, customers or suppliers of the Company, on the other hand, which is required to be described in the Registration Statement, the Time of Sale Prospectus and the Prospectus and which is not so described. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(bb)</B> <B><I>ERISA Compliance</I></B><B>.</B> . Each employee benefit plan, within the meaning of Section&nbsp;3(3) of the Employee
Retirement Income Security Act of 1974, as amended (&#147;<B>ERISA</B>&#148;), that is maintained, administered or contributed to by the Company or any of its affiliates for employees or former employees of the Company has been maintained in
material compliance with its terms and the requirements of any applicable statutes, orders, rules and regulations, including but not limited to, ERISA and the Internal Revenue Code of 1986, as amended (the &#147;<B>Code</B>&#148;). No prohibited
transaction, within the meaning of Section&nbsp;406 of ERISA or Section&nbsp;4975 of the Code, has occurred with respect to any such plan excluding transactions effected pursuant to a statutory or administrative exemption, including, without
limitation, pursuant to Section&nbsp;408 of ERISA and the regulatory guidance thereunder; and for each such plan that is subject to the funding rules of Section&nbsp;412 of the Code or Section&nbsp;302 of ERISA, no &#147;accumulated funding
deficiency&#148; as defined in Section&nbsp;412 of the Code has been incurred, whether or not waived, and the fair market value of the assets of each such plan (excluding for these purposes accrued but unpaid contributions) exceeds the present value
of all benefits accrued under such plan determined using reasonable actuarial assumptions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(cc)</B> <B><I>Payment of Taxes.</I></B>
All United States federal income tax returns of the Company and its subsidiaries required by law to be filed have been filed and all taxes shown by such returns or otherwise assessed, which are due and payable, have been paid, except assessments
against which appeals have been or will be promptly taken and as to which adequate reserves have been provided. The United States federal income tax returns of the Company for the past three tax years have been settled and no assessment
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in connection therewith has been made against the Company. The Company and its subsidiaries have filed all other tax returns that are required to have been filed by them pursuant to applicable
foreign, state, local or other law except insofar as the failure to file such returns would not result in a Material Adverse Effect, and has paid all taxes due pursuant to such returns or pursuant to any assessment received by the Company and its
subsidiaries, except for such taxes, if any, as are being contested in good faith and as to which adequate reserves have been established by the Company. The charges, accruals and reserves on the books of the Company in respect of any income and
corporation tax liability for any years not finally determined are adequate to meet any assessments or <FONT STYLE="white-space:nowrap">re-assessments</FONT> for additional income tax for any years not finally determined, except to the extent of any
inadequacy that would not result in a Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(dd)</B> <B><I>Company Not an
</I></B><B><I>&#147;</I></B><B><I>Investment Company.</I></B><B><I>&#148;</I></B> The Company is not required, and upon the issuance and sale of the Securities as herein contemplated and the application of the net proceeds therefrom as described in
the Registration Statement, the Time of Sale Prospectus and the Prospectus will not be required, to register as an &#147;investment company&#148; under the Investment Company Act of 1940, as amended (the &#147;<B>Investment Company Act</B>&#148;).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ee)</B> <B><I>No Price Stabilization or Manipulation</I></B><B><I>; Compliance with Regulation M</I></B><B>.</B> Neither the Company
nor any affiliate of the Company has taken, nor will the Company or any affiliate take, directly or indirectly, any action which is designed, or would be expected, to cause or result in, or which constitutes, the stabilization or manipulation of the
price of any security of the Company to facilitate the sale or resale of the Securities or to result in a violation of Regulation M under the Exchange Act. The Company has not effected any sales of Common Stock which are required to be disclosed in
response to Item 701 of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under the Securities Act which have not been so disclosed in the Registration Statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ff)</B> <B><I>Rated Debt</I></B><B>.</B> The Company has no debt securities or preferred stock that is rated by any &#147;nationally
recognized statistical rating agency&#148; (as that term is defined by the Commission for purposes of Section&nbsp;3(a)(62) the Exchange Act). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(gg)</B> <B><I>Related-Party Transactions</I></B><B>.</B> There are no business relationships or related-party transactions involving the
Company or any of its subsidiaries or any other person required to be described in the Registration Statement, the Time of Sale Prospectus or the Prospectus that have not been described as required.<U> </U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(hh)</B> <B><I>Accuracy of Exhibits</I></B><B>.</B> There are no contracts or documents which are required to be described in the
Registration Statement, the Time of Sale Prospectus or the Prospectus or to be filed as exhibits to the Registration Statement which have not been so described and filed as required. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> <B><I>Absence of Further Requirements</I></B><B>.</B> No filing with, or authorization, approval, consent, license, order,
registration, qualification or decree of, any Governmental Entity is necessary or required for the performance by the Company of its obligations hereunder, in connection with the offering, issuance or sale of the Securities hereunder or the
consummation of the transactions contemplated by this Agreement, except such as have been already obtained or as may be required under the Securities Act, the Securities Act Regulations, the rules of the Nasdaq Stock Market LLC, state securities
laws or the rules of Financial Industry Regulatory Authority, Inc. (&#147;<B>FINRA</B>&#148;). Except as described in the Registration Statement, the Time of Sale Prospectus or the Prospectus, neither the Company nor, to the Company&#146;s
knowledge, the Company&#146;s officers, directors or any of its affiliates (within the meaning of FINRA Conduct Rule 5121(f)(1)), directly or indirectly controls, is controlled by, or is under common control with, or is an associated person (within
the meaning of Article I, Section&nbsp;1(gg) of the <FONT STYLE="white-space:nowrap">By-laws</FONT> of FINRA) of, any member firm of FINRA. The Company is an &#147;experienced issuer&#148; as defined in Rule 5110(j)(6) of FINRA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(jj)</B> <B><I>Parties to <FONT STYLE="white-space:nowrap">Lock-Up</FONT>
Agreements</I></B><B>.</B> The Company has furnished to the Underwriters a letter agreement in the form attached hereto as <U>Exhibit</U><U></U><U>&nbsp;C</U> (the &#147;<B><FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement</B>&#148;) from
each of the persons listed on <U>Exhibit</U><U></U><U>&nbsp;D</U>. Such <U>Exhibit</U><U></U><U>&nbsp;D</U> lists under an appropriate caption the directors and officers of the Company. If any additional persons shall become directors or officers of
the Company prior to the end of the Company <FONT STYLE="white-space:nowrap">Lock-up</FONT> Period (as defined below), the Company shall cause each such person, prior to or contemporaneously with their appointment or election as a director or
officer of the Company, to execute and deliver to the Representatives a <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement.<B></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(kk)</B> <B><I>No Unlawful Contributions or Other Payments</I></B><B>.</B> Neither the Company nor any of its subsidiaries nor, to the best
of the Company&#146;s knowledge, any employee or agent of the Company or any subsidiary, has made any contribution or other payment to any official of, or candidate for, any federal, state or foreign office in violation of any law or of the
character required to be disclosed in the Registration Statement, the Time of Sale Prospectus or the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ll)</B>
<B><I>Foreign Corrupt Practices Act. </I></B>None of the Company, any of its subsidiaries or, to the knowledge of the Company, any director, officer, agent, employee, affiliate or other person acting on behalf of the Company or any of its
subsidiaries is aware of or has taken any action, directly or indirectly, that would result in a violation by such persons of the Foreign Corrupt Practices Act of 1977, as amended, and the rules and regulations thereunder (the
&#147;<B>FCPA</B>&#148;), including, without limitation, making use of the mails or any means or instrumentality of interstate commerce corruptly in furtherance of an offer, payment, promise to pay or authorization of the payment of any money, or
other property, gift, promise to give, or authorization of the giving of anything of value to any &#147;foreign official&#148; (as such term is defined in the FCPA) or any foreign political party or official thereof or any candidate for foreign
political office, in contravention of the FCPA and the Company and, to the knowledge of the Company, its affiliates have conducted their businesses in compliance with the FCPA and have instituted and maintain policies and procedures designed to
ensure, and which are reasonably expected to continue to ensure, continued compliance therewith. To the knowledge of the Company, no person associated or affiliated with or acting on behalf of the Company, including without limitation any director,
officer, agent or employee of the Company has, directly or indirectly, while acting on behalf of the Company (i)&nbsp;used any corporate funds for unlawful contributions, gifts, entertainment or other unlawful expenses relating to political
activity; or (ii)&nbsp;made any unlawful payment to domestic government officials or employees or to domestic political parties or campaigns from corporate funds. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(mm)</B> <B><I>Money Laundering Laws. </I></B>The operations of the Company and its subsidiaries are and have been conducted at all times
in compliance with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all jurisdictions, the rules and regulations thereunder and
any related or similar rules, regulations or guidelines, issued, administered or enforced by any Governmental Entity (collectively, the &#147;<B>Money Laundering Laws</B>&#148;); and no action, suit or proceeding by or before any Governmental Entity
involving the Company or any of its subsidiaries with respect to the Money Laundering Laws is pending or, to the best knowledge of the Company, threatened. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(nn)</B> <B><I>OFAC</I></B><B>. </B>None of the Company, any of its subsidiaries or, to the knowledge of the Company, any director,
officer, agent, employee or affiliate of the Company or any of its subsidiaries is an individual or entity (&#147;<B>Person</B>&#148;) currently the subject or target of any sanctions administered or enforced by the United States Government,
including, without limitation, the U.S. Department of the Treasury&#146;s Office of Foreign Assets Control (&#147;<B>OFAC</B>&#148;), the United Nations Security Council (&#147;<B>UNSC</B>&#148;), the European Union, Her Majesty&#146;s Treasury
(&#147;<B>HMT</B>&#148;), the Swiss Secretariat of Economic Affairs (&#147;<B>SECO</B>&#148;), or other relevant sanctions authority (collectively, &#147;<B>Sanctions</B>&#148;), nor is the Company located, organized or resident in a country or
territory that is the subject of Sanctions; and the Company will not directly or indirectly use the proceeds of the sale of the Shares, or lend, contribute or otherwise make available such proceeds to any
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
subsidiaries, joint venture partners or other Person, to fund any activities of or business with any Person, or in any country or territory, that, at the time of such funding, is the subject of
Sanctions or in any other manner that will result in a violation by any Person (including any Person participating in the transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions. For the past five years, the Company and its
subsidiaries have not knowingly engaged in and are not now knowingly engaged in any dealings or transactions with any person that at the time of the dealing or transaction is or was the subject or the target of Sanctions or with any Sanctioned
Country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(oo)</B> <B><I>Brokers</I></B><B>.</B> Except pursuant to this Agreement, there is no broker, finder or other party that is
entitled to receive from the Company any brokerage or finder&#146;s fee or other fee or commission as a result of any transactions contemplated by this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(pp)</B> <B><I>Forward-Looking Statements.</I></B> Each financial or operational projection or other &#147;forward-looking statement&#148;
(as defined by Section&nbsp;27A of the Securities Act or Section&nbsp;21E of the Exchange Act) contained in the Registration Statement, the Time of Sale Prospectus or the Prospectus (i)&nbsp;was so included by the Company in good faith and with
reasonable basis after due consideration by the Company of the underlying assumptions, estimates and other applicable facts and circumstances and (ii)&nbsp;is accompanied by meaningful cautionary statements identifying those factors that could cause
actual results to differ materially from those in such <FONT STYLE="white-space:nowrap">forward-looking</FONT> statement. No such statement was made with the knowledge of an executive officer or director of the Company that it was false or
misleading. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(qq)</B> <B><I>No Outstanding Loans or Other Extensions of Credit</I></B>. The Company does not have any outstanding
extension of credit, in the form of a personal loan, to or for any director or executive officer (or equivalent thereof) of the Company except for such extensions of credit as are expressly permitted by Section&nbsp;13(k) of the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(rr)</B> <B><I>Lending Relationship.</I></B><I> </I>Except as disclosed in the Registration Statement, the General Disclosure Package and
the Prospectus, the Company (i)&nbsp;does not have any&nbsp;material lending or other relationship with any bank or lending affiliate of any of the Underwriters and (ii)&nbsp;does not intend to use any of the proceeds from the sale of the Offered
Shares to repay any outstanding debt owed to any affiliate of any of the Underwriters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ss)</B> <B><I>Cybersecurity</I></B>. The
Company and its subsidiaries&#146; information technology assets and equipment, computers, systems, networks, hardware, software, websites, applications, and databases (collectively, &#147;<B>IT Systems</B>&#148;) are adequate for, and operate and
perform in all material respects as required in connection with the operation of the business of the Company and its subsidiaries as currently conducted, free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware and
other corruptants. The Company and its subsidiaries have implemented and maintained commercially reasonable physical, technical and administrative controls, policies, procedures, and safeguards to maintain and protect their material confidential
information and the integrity, continuous operation, redundancy and security of all IT Systems and data, including &#147;Personal Data,&#148; used in connection with their businesses. &#147;<B>Personal Data</B>&#148; means (i)&nbsp;a natural
person&#146;s name, street address, telephone number, <FONT STYLE="white-space:nowrap">e-mail</FONT> address, photograph, social security number or tax identification number, driver&#146;s license number, passport number, credit card number, bank
information, or customer or account number; (ii)&nbsp;any information which would qualify as &#147;personally identifying information&#148; under the Federal Trade Commission Act, as amended; (iii) &#147;personal data&#148; as defined by GDPR (as
defined below); (iv) any information which would qualify as &#147;protected health information&#148; under the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical
Health Act (collectively, &#147;<B>HIPAA&#148;</B>); and (v)&nbsp;any other piece of information that allows the identification of such natural person, or his or her family, or permits the collection or analysis of any data related to an identified
person&#146;s health or sexual orientation. There have been no breaches, violations, outages or unauthorized uses of or accesses to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
same, except for those that have been remedied without material cost or liability or the duty to notify any other person, nor any incidents under internal review or investigations relating to the
same. The Company and its subsidiaries are presently in material compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies
and contractual obligations relating to the privacy and security of IT Systems and Personal Data and to the protection of such IT Systems and Personal Data from unauthorized use, access, misappropriation or modification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(tt)</B> <B><I>Compliance with Data Privacy Laws</I></B>. The Company and its subsidiaries are, and at all prior times were, in material
compliance with all applicable state and federal data privacy and security laws and regulations, including without limitation HIPAA, and the Company and its subsidiaries have taken commercially reasonable actions to prepare to comply with, and since
May&nbsp;25, 2018, have been and currently are in compliance with, the European Union General Data Protection Regulation (&#147;<B>GDPR</B>&#148;) (EU 2016/679) (collectively, the &#147;<B>Privacy Laws</B>&#148;). To ensure compliance with the
Privacy Laws, the Company and its subsidiaries have in place, comply with, and take appropriate steps reasonably designed to ensure compliance in all material respects with their policies and procedures relating to data privacy and security and the
collection, storage, use, disclosure, handling, and analysis of Personal Data (the &#147;<B>Policies</B>&#148;). The Company and its subsidiaries have at all times made all disclosures to users or customers required by applicable laws and regulatory
rules or requirements, and none of such disclosures made or contained in any Policy have, to the knowledge of the Company, been inaccurate or in violation of any applicable laws and regulatory rules or requirements in any material respect. The
Company further certifies that neither it nor any subsidiary: (i)&nbsp;has received notice of any actual or potential liability under or relating to, or actual or potential violation of, any of the Privacy Laws, and has no knowledge of any event or
condition that would reasonably be expected to result in any such notice; (ii)&nbsp;is currently conducting or paying for, in whole or in part, any investigation, remediation, or other corrective action pursuant to any Privacy Law; or (iii)&nbsp;is
a party to any order, decree, or agreement that imposes any obligation or liability under any Privacy Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(uu)</B> <B><I>Deemed
Representation.</I></B> Any certificate signed by any officer of the Company delivered to the Underwriters or to counsel for the Underwriters pursuant to or in connection with this Agreement shall be deemed a representation and warranty by the
Company to the Underwriters as to the matters covered thereby as of the date or dates indicated in such certificate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(vv)</B>
<B><I>Statistical and Market-Related Data</I></B><B>.</B> Any statistical and market-related data included in the Registration Statement, the Time of Sale Prospectus or the Prospectus are based on or derived from sources that the Company believes,
after reasonable inquiry, to be reliable and accurate and, to the extent required, the Company has obtained the written consent to the use of such data from such sources. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ww)</B> <B><I>Company Stock Plans</I></B><B>.</B> With respect to the stock options (the &#147;<B>Stock Options</B>&#148;) granted
pursuant to the stock-based compensation plans of the Company and its subsidiaries (the &#147;<B>Company Stock Plans</B>&#148;) that are currently outstanding and not exercised, (i)&nbsp;each Stock Option intended to qualify as an &#147;incentive
stock option&#148; under Section&nbsp;422 of the Code so qualifies, (ii)&nbsp;each grant of a Stock Option was duly authorized no later than the date on which the grant of such Stock Option was by its terms to be effective (the &#147;<B>Grant
Date</B>&#148;) by all necessary corporate action, including, as applicable, approval by the board of directors of the Company (or a duly constituted and authorized committee thereof) and any required stockholder approval by the necessary number of
votes or written consents, and the award agreement governing such grant (if any) was duly executed and delivered by each party thereto, (iii)&nbsp;each such grant was made in accordance with the terms of the Company Stock Plans, the Exchange Act and
all other applicable laws and regulatory rules or requirements, including the rules of the Nasdaq Stock Market LLC and any other exchange on which Company securities are traded, and (iv)&nbsp;each such grant was properly accounted for in accordance
with GAAP in the financial statements (including the related notes) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the Company and disclosed in the Company&#146;s filings with the Commission in accordance with the Exchange Act and all other applicable laws. The Company has not knowingly granted, and there
is no and has been no policy or practice of the Company of granting, Stock Options prior to, or otherwise coordinating the grant of Stock Options with, the release or other public announcement of material information regarding the Company or its
subsidiaries or their results of operations or prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(xx)</B> <B><I>Cuba</I></B><B>.</B> The Company does not do business with
the government of Cuba or with any person located in Cuba within the meaning of Section&nbsp;517.075, Florida Statutes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(yy)</B>
<B><I>Anti-Takeover</I></B><B>.</B> The Company and its board of directors have taken all necessary action, if any, in order to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a
rights agreement) or other similar anti-takeover provision under the Company&#146;s charter documents or the laws of its state of incorporation that is or could reasonably be expected to become applicable to the Underwriters as a result of the
Underwriters and the Company fulfilling their respective obligations or exercising their respective rights under this Agreement, including, without limitation, the Company&#146;s issuance of the Securities and the Underwriters&#146; ownership of the
Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;2.</B> <B>Purchase, Sale and Delivery of the Offered Shares</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B><I>The Firm Shares</I></B><B>.</B> Upon the terms herein set forth, the Company agrees to issue and sell to the several
Underwriters an aggregate of 17,500,000 Firm Shares. On the basis of the representations, warranties and agreements herein contained, and upon the terms but subject to the conditions herein set forth, the Underwriters agree, severally and not
jointly, to purchase from the Company the respective number of Firm Shares set forth opposite their names on <U>Schedule</U><B><U> </U></B><U>A</U>. The purchase price per Firm Share to be paid by the several Underwriters to the Company shall be
$2.444 per share.<B> </B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B><I>The First Closing Date</I></B><B>.</B> Delivery of certificates for the Firm Shares to be
purchased by the Underwriters and payment therefor shall be made at the offices of Goodwin Procter LLP, 620 Eighth Avenue, New York, New York 10018 (or such other place as may be agreed to by the Company and the Representatives) at 10:00 a.m. New
York City time, on December&nbsp;6, 2021 or such other time and date as the Representatives shall designate by notice to the Company (the time and date of such closing are called the &#147;<B>First Closing Date</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B><I>The Optional Shares; Option Closing Date</I></B><B>.</B> In addition, on the basis of the representations, warranties and
agreements herein contained, and upon the terms but subject to the conditions herein set forth, the Company hereby grants an option to the several Underwriters to purchase, severally and not jointly, up to an aggregate of 2,625,000 Optional Shares
from the Company at the purchase price per share to be paid by the Underwriters for the Firm Shares, less an amount per share equal to any dividend or distribution declared by the Company and payable on the Firm Shares but not payable on Optional
Shares. The option granted hereunder may be exercised at any time and from time to time in whole or in part upon notice by the Representatives to the Company, which notice may be given at any time within 30&nbsp;days from the date of this Agreement.
Such notice shall set forth (i)&nbsp;the aggregate number of Optional Shares as to which the Underwriters are exercising the option and (ii)&nbsp;the time, date and place at which certificates for the Optional Shares will be delivered (which time
and date may be simultaneous with, but not earlier than, the First Closing Date; and in the event that such time and date are simultaneous with the First Closing Date, the term &#147;<B>First Closing Date</B>&#148; shall refer to the time and date
of delivery of certificates for the Firm Shares and such Optional Shares). Any such time and date of delivery, if subsequent to the First Closing Date, is called an &#147;<B>Option Closing Date</B>,&#148; and shall be determined by the
Representatives and shall not be earlier than three or later than five full business days after delivery of such notice of exercise. If any Optional Shares are to be purchased, each Underwriter agrees, severally and not
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
jointly, to purchase the number of Optional Shares (subject to such adjustments to eliminate fractional shares as the Representatives may determine) that bears the same proportion to the total
number of Optional Shares to be purchased as the number of Firm Shares set forth on <U>Schedule A</U> opposite the name of such Underwriter bears to the total number of Firm Shares. The Representatives may cancel the option at any time prior to its
expiration by giving written notice of such cancellation to the Company.<B> </B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B><I>Public Offering of the Offered
Shares</I></B><B>.</B> The Representatives hereby advises the Company that the Underwriters intend to offer for sale to the public, initially on the terms set forth in the Registration Statement, the Time of Sale Prospectus and the Prospectus, their
respective portions of the Offered Shares as soon after this Agreement has been executed as the Representatives, in their sole judgment, have determined is advisable and practicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B><I>Payment for the Offered Shares</I></B><B>.</B> (i)&nbsp;Payment for the Offered Shares to be sold by the Company shall be
made at the First Closing Date (and, if applicable, at each Option Closing Date) by wire transfer of immediately available funds to the order of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) It is understood that the Representatives have been authorized, for their own account and the accounts of the several Underwriters, to
accept delivery of and receipt for, and make payment of the purchase price for, the Firm Shares and any Optional Shares the Underwriters have agreed to purchase. Each of Jefferies, Stifel and Wells Fargo, individually and not as the Representatives
of the Underwriters, may (but shall not be obligated to) make payment for any Offered Shares to be purchased by any Underwriter whose funds shall not have been received by the Representatives by the First Closing Date or the applicable Option
Closing Date, as the case may be, for the account of such Underwriter, but any such payment shall not relieve such Underwriter from any of its obligations under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> <B><I>Delivery of the Offered Shares</I></B><B>.</B> The Company shall deliver, or cause to be delivered to the Representatives for
the accounts of the several Underwriters certificates for the Firm Shares at the First Closing Date, against release of a wire transfer of immediately available funds for the amount of the purchase price therefor. The Company shall also deliver, or
cause to be delivered to the Representatives for the accounts of the several Underwriters, certificates for the Optional Shares the Underwriters have agreed to purchase at the First Closing Date or the applicable Option Closing Date, as the case may
be, against the release of a wire transfer of immediately available funds for the amount of the purchase price therefor. If the Representatives so elect, delivery of the Offered Shares may be made by credit to the accounts designated by the
Representatives through The Depository Trust Company&#146;s full fast transfer or DWAC programs. If the Representatives so elect, the certificates for the Offered Shares shall be registered in such names and denominations as the Representatives
shall have requested at least two full business days prior to the First Closing Date (or the applicable Option Closing Date, as the case may be) and shall be made available for inspection on the business day preceding the First Closing Date (or the
applicable Option Closing Date, as the case may be) at a location in New York City as the Representatives may designate. Time shall be of the essence, and delivery at the time and place specified in this Agreement is a further condition to the
obligations of the Underwriters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.</B> <B>Additional Covenants </B><B>of the Company</B><B>.</B><B>
</B>The Company further covenants and agrees with each Underwriter as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B><I>Delivery of Registration Statement, Time
of Sale Prospectus and Prospectus</I></B><B><I>.</I></B><I> </I>The Company shall furnish to you in New York City, without charge, prior to 10:00 a.m. New York City time on the business day next succeeding the date of this Agreement and during the
period when a prospectus relating to the Offered Shares is required by the Securities Act to be delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule) in connection with sales of the Offered
Shares, as many copies of the Time of Sale Prospectus, the Prospectus and any supplements and amendments thereto or to the Registration Statement as you may reasonably request. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B><I>Representatives</I></B><B><I>&#146;</I></B><B><I> Review of Proposed
Amendments and Supplements</I></B><B><I>.</I></B><I> </I>During the period when a prospectus relating to the Offered Shares is required by the Securities Act to be delivered (whether physically or through compliance with Rule 172 under the
Securities Act or any similar rule), the Company (i)&nbsp;will furnish to the Representatives for review, a reasonable period of time prior to the proposed time of filing of any proposed amendment or supplement to the Registration Statement, a copy
of each such amendment or supplement and (ii)&nbsp;will not amend or supplement the Registration Statement (including any amendment or supplement through incorporation of any report filed under the Exchange Act) without the Representatives&#146;
prior written consent, which shall not be unreasonably withheld, conditioned or delayed. Prior to amending or supplementing any preliminary prospectus, the Time of Sale Prospectus or the Prospectus (including any amendment or supplement through
incorporation of any report filed under the Exchange Act), the Company shall furnish to the Representatives for review, a reasonable amount of time prior to the time of filing or use of the proposed amendment or supplement, a copy of each such
proposed amendment or supplement. The Company shall not file or use any such proposed amendment or supplement without the Representatives&#146; prior written consent, which shall not be unreasonably withheld, conditioned or delayed. The Company
shall file with the Commission within the applicable period specified in Rule 424(b) under the Securities Act any prospectus required to be filed pursuant to such Rule. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B><I>Free Writing Prospectuses</I></B><B><I>.</I></B><I> </I>The Company shall furnish to the Representatives for review, a
reasonable amount of time prior to the proposed time of filing or use thereof, a copy of each proposed free writing prospectus or any amendment or supplement thereto prepared by or on behalf of, used by, or referred to by the Company, and the
Company shall not file, use or refer to any proposed free writing prospectus or any amendment or supplement thereto without the Representatives&#146; prior written consent, which shall not be unreasonably withheld, conditioned or delayed. The
Company shall furnish to each Underwriter, without charge, as many copies of any free writing prospectus prepared by or on behalf of, used by or referred to by the Company as such Underwriter may reasonably request. If at any time when a prospectus
is required by the Securities Act to be delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule) in connection with sales of the Offered Shares (but in any event if at any time through and
including the First Closing Date) there occurred or occurs an event or development as a result of which any free writing prospectus prepared by or on behalf of, used by, or referred to by the Company conflicted or would conflict with the information
contained in the Registration Statement or included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances
prevailing at such time, not misleading, the Company shall promptly amend or supplement such free writing prospectus to eliminate or correct such conflict or so that the statements in such free writing prospectus as so amended or supplemented will
not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances prevailing at such time, not misleading, as the case may be; <I>provided,
however</I>, that prior to amending or supplementing any such free writing prospectus, the Company shall furnish to the Representatives for review, a reasonable amount of time prior to the proposed time of filing or use thereof, a copy of such
proposed amended or supplemented free writing prospectus, and the Company shall not file, use or refer to any such amended or supplemented free writing prospectus without the Representatives&#146; prior written consent, which shall not be
unreasonably withheld, conditioned or delayed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B><I>Filing of Underwriter Free Writing Prospectuses.</I></B><I> </I>The
Company shall not take any action that would result in an Underwriter or the Company being required to file with the Commission pursuant to Rule 433(d) under the Securities Act a free writing prospectus prepared by or on behalf of such Underwriter
that such Underwriter otherwise would not have been required to file thereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B><I>Amendments and Supplements to Time of Sale
Prospectus</I></B><B><I>.</I></B><I> </I>If the Time of Sale Prospectus is being used to solicit offers to buy the Offered Shares at a time when the Prospectus is not yet available to prospective purchasers, and any event shall occur or condition
exist as a result of which it is necessary to amend or supplement the Time of Sale Prospectus so that the Time of Sale Prospectus does not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the
statements therein, in the light of the circumstances when delivered to a prospective purchaser, not misleading, or if any event shall occur or condition exist as a result of which the Time of Sale Prospectus conflicts with the information contained
in the Registration Statement, or if, in the opinion of counsel for the Underwriters, it is necessary to amend or supplement the Time of Sale Prospectus to comply with applicable law, the Company shall (subject to Section&nbsp;3(b) and
Section&nbsp;3(c) hereof) promptly prepare, file with the Commission and furnish, at its own expense, to the Underwriters and to any dealer upon request, either amendments or supplements to the Time of Sale Prospectus so that the statements in the
Time of Sale Prospectus as so amended or supplemented will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when delivered to a
prospective purchaser, not misleading or so that the Time of Sale Prospectus, as amended or supplemented, will no longer conflict with the information contained in the Registration Statement, or so that the Time of Sale Prospectus, as amended or
supplemented, will comply with applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> <B><I>Certain Notifications and Required Actions</I></B><B>.</B> After the date
of this Agreement, the Company shall promptly advise the Representatives in writing of: (i)&nbsp;the receipt of any comments of, or requests for additional or supplemental information from, the Commission; (ii)&nbsp;the time and date of any filing
of any post-effective amendment to the Registration Statement or any amendment or supplement to any preliminary prospectus, the Time of Sale Prospectus, any free writing prospectus or the Prospectus; (iii)&nbsp;the time and date that any
post-effective amendment to the Registration Statement becomes effective; and (iv)&nbsp;the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto or any
amendment or supplement to any preliminary prospectus, the Time of Sale Prospectus or the Prospectus or of any order preventing or suspending the use of any preliminary prospectus, the Time of Sale Prospectus, any free writing prospectus or the
Prospectus, or of any proceedings to remove, suspend or terminate from listing or quotation the Shares from any securities exchange upon which they are listed for trading or included or designated for quotation, or of the threatening or initiation
of any proceedings for any of such purposes. If the Commission shall enter any such stop order at any time, the Company will use its best efforts to obtain the lifting of such order at the earliest possible moment. Additionally, the Company agrees
that it shall comply with all applicable provisions of Rule&nbsp;424(b), Rule 433 and Rule 430A or Rule 430B under the Securities Act and will use its reasonable efforts to confirm that any filings made by the Company under Rule 424(b) or Rule 433
were received in a timely manner by the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> <B><I>Amendments and Supplements to the Prospectus and Other Securities
Act Matters</I></B><B><I>.</I></B> If any event shall occur or condition exist as a result of which it is necessary to amend or supplement the Prospectus so that the Prospectus does not include an untrue statement of a material fact or omit to state
a material fact necessary in order to make the statements therein, in the light of the circumstances when the Prospectus is delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule) to a
purchaser, not misleading, or if in the opinion of the Representatives or counsel for the Underwriters it is otherwise necessary to amend or supplement the Prospectus to comply with applicable law, the Company agrees (subject to Section&nbsp;3(b)
and Section&nbsp;3(c)) hereof to promptly prepare, file with the Commission and furnish, at its own expense, to the Underwriters and to any dealer upon request, amendments or supplements to the Prospectus so that the statements in the Prospectus as
so amended or supplemented will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when the Prospectus is delivered (whether
physically or through compliance with Rule 172 under the Securities Act </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or any similar rule) to a purchaser, not misleading or so that the Prospectus, as amended or supplemented, will comply with applicable law. Neither the Representative&#146;s consent to, nor
delivery of, any such amendment or supplement shall constitute a waiver of any of the Company&#146;s obligations under Section&nbsp;3(b) or Section&nbsp;3(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> <B><I>Blue Sky Compliance</I></B><B>.</B> The Company shall cooperate with the Representatives and counsel for the Underwriters to
qualify or register the Offered Shares for sale under (or obtain exemptions from the application of) the state securities or blue sky laws or Canadian provincial securities laws of those jurisdictions designated by the Representatives, shall comply
with such laws and shall continue such qualifications, registrations and exemptions in effect so long as required for the distribution of the Offered Shares. The Company shall not be required to qualify as a foreign corporation or to take any action
that would subject it to general service of process in any such jurisdiction where it is not presently qualified. The Company will advise the Representatives promptly of the suspension of the qualification or registration of (or any such exemption
relating to) the Offered Shares for offering, sale or trading in any jurisdiction or any initiation or threat of any proceeding for any such purpose, and in the event of the issuance of any order suspending such qualification, registration or
exemption, the Company shall use its best efforts to obtain the withdrawal thereof at the earliest possible moment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B><I>Use
of Proceeds</I></B><B>.</B> The Company shall apply the net proceeds from the sale of the Offered Shares sold by it in the manner described under the caption &#147;Use of Proceeds&#148; in the Registration Statement, the Time of Sale Prospectus and
the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j)</B> <B><I>Transfer Agent</I></B><B>.</B> The Company shall engage and maintain, at its expense, a registrar and
transfer agent for the Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k)</B> <B><I>Earnings Statement</I></B><B>.</B> The Company will make generally available to its
security holders and to the Representatives as soon as practicable an earnings statement (which need not be audited) covering a period of at least twelve months beginning with the first fiscal quarter of the Company commencing after the date of this
Agreement that will satisfy the provisions of Section&nbsp;11(a) of the Securities Act and the rules and regulations of the Commission thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(l)</B> <B><I>Continued Compliance with Securities Laws</I></B><B>.</B> The Company will comply with the Securities Act and the Exchange
Act so as to permit the completion of the distribution of the Offered Shares as contemplated by this Agreement<B>, </B>the Registration Statement, the Time of Sale Prospectus and the Prospectus. Without limiting the generality of the foregoing, the
Company will, during the period when a prospectus relating to the Offered Shares is required by the Securities Act to be delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule), file on a
timely basis with the Commission and the NASDAQ all reports and documents required to be filed under the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(m)</B>
<B><I>Listing</I></B><B>.</B> The Company will use its best efforts to list, subject to notice of issuance, the Offered Shares on the NASDAQ. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(n)</B> <B><I>Company to Provide Copy of the Prospectus in Form That May be Downloaded from the Internet</I></B><B>.</B> If requested by
the Representatives, the Company shall cause to be prepared and delivered, at its expense, within one business day from the effective date of this Agreement, to the Representatives an &#147;<B>electronic Prospectus</B>&#148; to be used by the
Underwriters in connection with the offering and sale of the Offered Shares. As used herein, the term &#147;<B>electronic Prospectus</B>&#148; means a form of Time of Sale Prospectus, and any amendment or supplement thereto, that meets each of the
following conditions: (i)&nbsp;it shall be encoded in an electronic format, satisfactory to the Representatives, that may be transmitted electronically by the Representatives to offerees and purchasers of the Offered Shares; (ii)&nbsp;it shall
disclose </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the same information as the paper Time of Sale Prospectus, except to the extent that graphic and image material cannot be disseminated electronically, in which case such graphic and image
material shall be replaced in the electronic Prospectus with a fair and accurate narrative description or tabular representation of such material, as appropriate; and (iii)&nbsp;it shall be in or convertible into a paper format or an electronic
format, satisfactory to the Representatives, that will allow investors to store and have continuously ready access to the Time of Sale Prospectus at any future time, without charge to investors (other than any fee charged for subscription to the
Internet as a whole and for <FONT STYLE="white-space:nowrap">on-line</FONT> time). The Company hereby confirms that it has included or will include in the Prospectus filed pursuant to EDGAR or otherwise with the Commission and in the Registration
Statement at the time it was declared effective an undertaking that, upon receipt of a request by an investor or his or her representative, the Company shall transmit or cause to be transmitted promptly, without charge, a paper copy of the Time of
Sale Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(o)</B> <B><I>Agreement Not to Offer or Sell Additional Shares</I></B><B>.</B> During the period commencing on and
including the date hereof and continuing through and including the 90th day following the date of the Prospectus (such period, as extended as described below, being referred to herein as the &#147;<B><FONT STYLE="white-space:nowrap">Lock-up</FONT>
Period</B>&#148;), the Company will not, without the prior written consent of both Jefferies and Stifel (which consent may be withheld in their sole discretion), directly or indirectly: (i)&nbsp;sell, offer to sell, contract to sell or lend any
Shares or Related Securities (as defined below); (ii) effect any short sale, or establish or increase any &#147;put equivalent position&#148; (as defined in Rule <FONT STYLE="white-space:nowrap">16a-1(h)</FONT> under the Exchange Act) or liquidate
or decrease any &#147;call equivalent position&#148; (as defined in <FONT STYLE="white-space:nowrap">Rule&nbsp;16a-1(b)</FONT> under the Exchange Act) of any Shares or Related Securities; (iii)&nbsp;pledge, hypothecate or grant any security interest
in any Shares or Related Securities; (iv)&nbsp;in any other way transfer or dispose of any Shares or Related Securities; (v)&nbsp;enter into any swap, hedge or similar arrangement or agreement that transfers, in whole or in part, the economic risk
of ownership of any Shares or Related Securities, regardless of whether any such transaction is to be settled in securities, in cash or otherwise; (vi)&nbsp;announce the offering of any Shares or Related Securities; (vii)&nbsp;submit or file any
registration statement under the Securities Act in respect of any Shares or Related Securities (other than as contemplated by this Agreement with respect to the Offered Shares); (viii) effect a reverse stock split, recapitalization, share
consolidation, reclassification or similar transaction affecting the outstanding Shares; or (ix)&nbsp;publicly announce the intention to do any of the foregoing; <I>provided, however</I>, that the Company may (A)&nbsp;effect the transactions
contemplated hereby, (B)&nbsp;issue Shares or options to purchase Shares, or issue Shares upon exercise of options, pursuant to any stock option, stock bonus or other stock plan or arrangement described in the Registration Statement, the Time of
Sale Prospectus and the Prospectus, and (C)&nbsp;issue Shares or Related Securities upon the conversion, exercise or exchange of convertible, exercisable or exchangeable securities outstanding as of the date of this Agreement. For purposes of the
foregoing, &#147;<B>Related Securities</B>&#148; shall mean any options or warrants or other rights to acquire Shares or any securities exchangeable or exercisable for or convertible into Shares, or to acquire other securities or rights ultimately
exchangeable or exercisable for, or convertible into, Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(p)</B> <B><I>Future Reports to the
</I></B><B><I>Representatives</I></B><B><I>.</I></B><I> </I>During the period of five years hereafter, the Company will furnish to the Representatives: (i)&nbsp;as soon as practicable after the end of each fiscal year, copies of the Annual Report of
the Company containing the balance sheet of the Company as of the close of such fiscal year and statements of income, stockholders&#146;<I> </I>equity and cash flows for the year then ended and the opinion thereon of the Company&#146;s independent
public or certified public accountants; (ii)&nbsp;as soon as practicable after the filing thereof, copies of each proxy statement, Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> Quarterly Report on Form <FONT
STYLE="white-space:nowrap">10-Q,</FONT> Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> or other report filed by the Company with the Commission, FINRA or any securities exchange; and (iii)&nbsp;as soon as available, copies of any
report or communication of the Company furnished or made available generally to holders of its capital stock; <I>provided, however,</I> that the requirements of this Section&nbsp;3(p) shall be satisfied to the extent that such reports, statement,
communications, financial statements or other documents are available on EDGAR. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(q)</B> <B><I>Investment Limitation</I></B><B>.</B> The Company shall not invest or
otherwise use the proceeds received by the Company from its sale of the Offered Shares in such a manner as would require the Company or any of its subsidiaries to register as an investment company under the Investment Company Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(r)</B> <B><I>No Stabilization or Manipulation</I></B><B><I>; Compliance with Regulation M</I></B><B>.</B> The Company will not take, and
will ensure that no affiliate of the Company will take, directly or indirectly, any action designed to or that might cause or result in stabilization or manipulation of the price of the Shares or any reference security with respect to the Shares,
whether to facilitate the sale or resale of the Offered Shares or otherwise, and the Company will, and shall cause each of its affiliates to, comply with all applicable provisions of Regulation M. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(s)</B> <B><I>Enforce <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement</I></B><B><I>s</I></B><B>.</B> The Company will direct the
transfer agent to place stop transfer restrictions upon any securities of the Company that are bound by <FONT STYLE="white-space:nowrap">&#147;lock-up&#148;</FONT> agreements for the duration of the periods contemplated in such agreements,
including, without limitation, <FONT STYLE="white-space:nowrap">&#147;lock-up&#148;</FONT> agreements entered into by the Company&#146;s officers, directors and securityholders pursuant to Section&nbsp;6(i) hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(t)</B> <B><I>Amendments and Supplements to Permitted Section</I></B><B><I></I></B><B><I>&nbsp;5(d) Communications. </I></B><I></I>If at
any time following the distribution of any Permitted Section&nbsp;5(d) Communication, there occurred or occurs an event or development as a result of which such Permitted Section&nbsp;5(d) Communication included or would include an untrue statement
of a material fact or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances existing at that subsequent time, not misleading, the Company will promptly notify the
Representatives and will promptly amend or supplement, at its own expense, such Permitted Section&nbsp;5(d) Communication to eliminate or correct such untrue statement or omission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Representatives, on behalf of the several Underwriters, may, in their sole discretion, waive in writing the performance by the Company of
any one or more of the foregoing covenants or extend the time for their performance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.</B> <B>Payment of
Expenses</B><B>.</B> The Company agrees to pay all costs, fees and expenses incurred in connection with the performance of its obligations hereunder and in connection with the transactions contemplated hereby, including without limitation
(i)&nbsp;all expenses incident to the issuance and delivery of the Offered Shares (including all printing and engraving costs), (ii)&nbsp;all fees and expenses of the registrar and transfer agent of the Shares, (iii)&nbsp;all necessary issue,
transfer and other stamp taxes in connection with the issuance and sale of the Offered Shares to the Underwriters, (iv)&nbsp;all fees and expenses of the Company&#146;s counsel, independent public or certified public accountants and other advisors,
(v)&nbsp;all costs and expenses incurred in connection with the preparation, printing, filing, shipping and distribution of the Registration Statement (including financial statements, exhibits, schedules, consents and certificates of experts), the
Time of Sale Prospectus, the Prospectus, each free writing prospectus prepared by or on behalf of, used by, or referred to by the Company, and each preliminary prospectus, each Permitted Section&nbsp;5(d) Communication, and all amendments and
supplements thereto, and this Agreement, (vi)&nbsp;all filing fees, attorneys&#146; fees and expenses incurred by the Company or the Underwriters in connection with qualifying or registering (or obtaining exemptions from the qualification or
registration of) all or any part of the Offered Shares for offer and sale under the state securities or blue sky laws or the provincial securities laws of Canada, and, if requested by the Representatives, preparing and printing a &#147;Blue Sky
Survey&#148; or memorandum and a &#147;Canadian wrapper&#148;, and any supplements thereto, advising the Underwriters of such qualifications, registrations and exemptions, (vii)&nbsp;the costs, fees and expenses incurred by the Underwriters in
connection with determining their compliance with the rules and regulations of FINRA related to the Underwriters&#146; participation in the offering and distribution of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Offered Shares, including any related filing fees and up to $10,000 of legal fees of, and disbursements by, counsel to the Underwriters<B>,</B> (viii)&nbsp;the costs and expenses of the Company
relating to investor presentations on any &#147;road show&#148;, any Permitted Section&nbsp;5(d) Communication or any Section&nbsp;5(d) Oral Communication undertaken in connection with the offering of the Offered Shares, including, without
limitation, expenses associated with the preparation or dissemination of any electronic road show, expenses associated with the production of road show slides and graphics, fees and expenses of any consultants engaged in connection with the road
show presentations with the prior approval of the Company, travel and lodging expenses of the representatives, employees and officers of the Company and any such consultants, and the cost of any aircraft chartered in connection with the road show,
(ix)&nbsp;the fees and expenses associated with listing the Offered Shares on the NASDAQ, and (x)&nbsp;all other fees, costs and expenses of the nature referred to in Item 14 of Part&nbsp;II of the Registration Statement. Except as provided in this
Section&nbsp;4 or in Section&nbsp;7, Section&nbsp;9 or Section&nbsp;10 hereof, the Underwriters shall pay their own expenses, including the fees and disbursements of their counsel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.</B> <B>Covenant of the Underwriters</B><B>.</B> Each Underwriter severally and not jointly covenants with the
Company not to take any action that would result in the Company being required to file with the Commission pursuant to Rule 433(d) under the Securities Act a free writing prospectus prepared by or on behalf of such Underwriter that otherwise would
not, but for such actions, be required to be filed by the Company under Rule 433(d). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;6.</B> <B>Conditions
of the Obligations of the Underwriters</B><B>.</B> The respective obligations of the several Underwriters hereunder to purchase and pay for the Offered Shares as provided herein on the First Closing Date and, with respect to the Optional Shares,
each Option Closing Date, shall be subject to the accuracy of the representations and warranties on the part of the Company set forth in Section&nbsp;1 hereof as of the date hereof and as of the First Closing Date as though then made and, with
respect to the Optional Shares, as of each Option Closing Date as though then made, to the timely performance by the Company of its covenants and other obligations hereunder, and to each of the following additional conditions: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B><I>Comfort Letter</I></B><B>.</B> On the date hereof, the Representatives shall have received from BDO USA, LLP, independent
registered public accountants for the Company, a letter dated the date hereof addressed to the Underwriters, in form and substance satisfactory to the Representatives, containing statements and information of the type ordinarily included in
accountant&#146;s &#147;comfort letters&#148; to underwriters, delivered according to Statement of Auditing Standards No.&nbsp;72 (or any successor bulletin), with respect to the audited and unaudited financial statements and certain financial
information contained in the Registration Statement, the Time of Sale Prospectus, and each free writing prospectus, if any. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)
</B><B><I>Compliance with Registration Requirements; No Stop Order; No Objection from </I></B><B></B><B><I>FINRA</I></B><B></B><B><I>. </I></B><B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) The Company shall have filed the Prospectus with the Commission (including the information required by Rule 430A or Rule 430B under the
Securities Act) in the manner and within the time period required by Rule 424(b) under the Securities Act; or the Company shall have filed a <FONT STYLE="white-space:nowrap">post-effective</FONT> amendment to the Registration Statement containing
the information required by such Rule 430A or Rule 430B, and such post-effective amendment shall have become effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) No stop
order suspending the effectiveness of the Registration Statement or any post-effective amendment to the Registration Statement shall be in effect, and no proceedings for such purpose shall have been instituted or threatened by the Commission. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) If a filing has been made with FINRA, FINRA shall have raised no objection to the
fairness and reasonableness of the underwriting terms and arrangements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B><I>No Material Adverse Change or Ratings Agency
Change</I></B><B>.</B> For the period from and after the date of this Agreement and through and including the First Closing Date and, with respect to any Optional Shares purchased after the First Closing Date, each Option Closing Date: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) in the judgment of the Representatives there shall not have occurred any Material Adverse Change; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) there shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential downgrading or of any
review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries by any &#147;nationally recognized statistical rating organization&#148; as
that term is used in <FONT STYLE="white-space:nowrap">Rule&nbsp;15c3-1(c)(2)(vi)(F)</FONT> under the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>
<B><I>Opinion of Counsel for the Company</I></B><B>.</B> On each of the First Closing Date and each Option Closing Date the Representatives shall have received the opinion of Morgan, Lewis&nbsp;&amp; Bockius LLP, counsel for the Company, dated as of
such date, in the form attached hereto as <U>Exhibit A</U> and to such further effect as the Representatives shall reasonably request. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B><I>Opinion of </I></B><B><I>Intellectual Property Counsel for the Company</I></B><B><I>.</I></B><I> </I>On each of the First
Closing Date and each Option Closing Date, the Representatives shall have received the opinion of each of (i)&nbsp;Wilson Sonsini Goodrich&nbsp;&amp; Rosati and (ii)&nbsp;Morgan, Lewis&nbsp;&amp; Bockius LLP, counsel for the Company with respect to
intellectual property matters, dated as of such date, in the form attached hereto as <U>Exhibit <FONT STYLE="white-space:nowrap">B-1</FONT></U> and <U>Exhibit <FONT STYLE="white-space:nowrap">B-2</FONT></U>, respectively, and to such further effect
as the Representatives shall reasonably request. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> <B><I>Opinion of Counsel for the Underwriters</I></B><B>.</B> On each of the
First Closing Date and each Option Closing Date the Representatives shall have received the opinion of Goodwin Procter LLP, counsel for the Underwriters in connection with the offer and sale of the Offered Shares, in form and substance satisfactory
to the Underwriters, dated as of such date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> <B><I>Officers</I></B><B><I>&#146;</I></B><B><I> Certificate</I></B><B>.</B> On
each of the First Closing Date and each Option Closing Date, the Representatives shall have received a certificate executed by the Chief Executive Officer or President of the Company and the Chief Financial Officer of the Company, dated as of such
date, to the effect set forth in Section&nbsp;6(b)(ii) and further to the effect that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) for the period from and including the date of
this Agreement through and including such date, there has not occurred any Material Adverse Change; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) the representations, warranties
and covenants of the Company set forth in Section&nbsp;1 of this Agreement are true and correct with the same force and effect as though expressly made on and as of such date; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) the Company has complied with all the agreements hereunder and satisfied all the conditions on its part to be performed or satisfied
hereunder at or prior to such date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> <B><I>Bring-down Comfort Letter</I></B><B>.</B> On each of the First Closing Date and each
Option Closing Date the Representatives shall have received from BDO USA, LLP, independent registered public accountants for the Company, a letter dated such date, in form and substance satisfactory to the Representatives, which letter shall:
(i)&nbsp;reaffirm the statements made in the letter furnished by them </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
pursuant to Section&nbsp;6(a), except that the specified date referred to therein for the carrying out of procedures shall be no more than three business days prior to the First Closing Date or
the applicable Option Closing Date, as the case may be; and (ii)&nbsp;cover certain financial information contained in the Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B><I><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements</I></B><B><I>.</I></B> On or prior to the date hereof, the Company
shall have furnished to the Representatives an agreement in the form of <U>Exhibit C</U> hereto from each of the persons listed on <U>Exhibit D</U> hereto, and each such agreement shall be in full force and effect on each of the First Closing Date
and each Option Closing Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j)</B> <B><I>Chief Financial Officer&#146;s Certificate</I></B><B>.</B><B> </B>On the date hereof and
on each of the First Closing Date and each Option Closing Date, the Representatives shall have received a certificate from the Chief Financial Officer of the Company, in form and substance reasonably satisfactory to counsel for the Underwriters,
with respect to certain financial data contained in the Registration Statement, the Time of Sale Prospectus or the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k)</B>
<B><I>Secretary&#146;s Certificate</I></B>. On each of the First Closing Date and each Option Closing Date, the Representatives shall have received a certificate from the Secretary of the Company, in form and substance reasonably satisfactory to
counsel for the Underwriters and customary for the type of offering contemplated by this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(l)</B>
<B><I>Rule</I></B><B><I></I></B><B><I>&nbsp;462(b) Registration Statement</I></B>. In the event that a Rule&nbsp;462(b) Registration Statement is filed in connection with the offering contemplated by this Agreement, such Rule&nbsp;462(b)
Registration Statement shall have been filed with the Commission on the date of this Agreement and shall have become effective automatically upon such filing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(m)</B> <B><I>Additional Documents</I></B>. On or before each of the First Closing Date and each Option Closing Date, the Representatives
and counsel for the Underwriters shall have received such information, documents and opinions as they may reasonably request for the purposes of enabling them to pass upon the issuance and sale of the Offered Shares as contemplated herein, or in
order to evidence the accuracy of any of the representations and warranties, or the satisfaction of any of the conditions or agreements, herein contained; and all proceedings taken by the Company in connection with the issuance and sale of the
Offered Shares as contemplated herein and in connection with the other transactions contemplated by this Agreement shall be satisfactory in form and substance to the Representatives and counsel for the Underwriters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any condition specified in this Section&nbsp;6 is not satisfied when and as required to be satisfied, this Agreement may be terminated by
the Representatives by notice from the Representatives to the Company at any time on or prior to the First Closing Date and, with respect to the Optional Shares, at any time on or prior to the applicable Option Closing Date, which termination shall
be without liability on the part of any party to any other party, except that Section&nbsp;4, Section&nbsp;7, Section&nbsp;9 and Section&nbsp;10 shall at all times be effective and shall survive such termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;7.</B> <B>Reimbursement of Underwriters</B><B>&#146;</B><B> Expenses</B>. If this Agreement is terminated by the
Representatives pursuant to Section&nbsp;6, Section&nbsp;11 or Section&nbsp;12, or if the sale to the Underwriters of the Offered Shares on the First Closing Date is not consummated because of any refusal, inability or failure on the part of the
Company to perform any agreement herein or to comply with any provision hereof, the Company agrees to reimburse the Representatives and the other Underwriters (or such Underwriters as have terminated this Agreement with respect to themselves), in
each case, except for any defaulting Underwriters pursuant to Section&nbsp;11, severally, upon demand for all <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses that shall have been reasonably
incurred by the Representatives and the Underwriters in connection with the proposed purchase and the offering and sale of the Offered Shares, including, but not limited to, fees and disbursements of counsel, printing expenses, travel expenses,
postage, facsimile and telephone charges. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8.</B> <B>Effectiveness of this Agreement</B>. This Agreement
shall become effective upon&nbsp;the execution and delivery hereof by the parties hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;9.</B>
<B>Indemnification</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B><I>Indemnification of the Underwriters</I></B><B>.</B> The Company agrees to indemnify and hold
harmless each Underwriter, its affiliates, directors, officers, employees and agents, and each person, if any, who controls any Underwriter within the meaning of the Securities Act or the Exchange Act against any loss, claim, damage, liability or
expense, as incurred, to which such Underwriter or such affiliate, director, officer, employee, agent or controlling person may become subject, under the Securities Act, the Exchange Act, other federal or state statutory law or regulation, or the
laws or regulations of foreign jurisdictions where Offered Shares have been offered or sold or at common law or otherwise (including in settlement of any litigation, if such settlement is effected with the written consent of the Company), insofar as
such loss, claim, damage, liability or expense (or actions in respect thereof as contemplated below) arises out of or is based upon (i)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement,
or any amendment thereto, or the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading; or (ii)&nbsp;any untrue statement or alleged untrue statement of
a material fact included in any preliminary prospectus, the Time of Sale Prospectus, any free writing prospectus that the Company has used, referred to or filed, or is required to file, pursuant to Rule 433(d) of the Securities Act, any Marketing
Material, any Section&nbsp;5(d) Written Communication or the Prospectus (or any amendment or supplement to the foregoing), or the omission or alleged omission to state therein a material fact necessary in order to make the statements, in the light
of the circumstances under which they were made, not misleading; or (iii)&nbsp;any act or failure to act or any alleged act or failure to act by any Underwriter in connection with, or relating in any manner to, the Shares or the offering
contemplated hereby, and which is included as part of or referred to in any loss, claim, damage, liability or action arising out of or based upon any matter covered by clause (i)&nbsp;or (ii) above; and to reimburse each Underwriter and each such
affiliate, director, officer, employee, agent and controlling person for any and all expenses (including the fees and disbursements of counsel) as such expenses are incurred by such Underwriter or such affiliate, director, officer, employee, agent
or controlling person in connection with investigating, defending, settling, compromising or paying any such loss, claim, damage, liability, expense or action; <I>provided, however</I>, that the foregoing indemnity agreement shall not apply to any
loss, claim, damage, liability or expense to the extent, but only to the extent, arising out of or based upon any untrue statement or alleged untrue statement or omission or alleged omission made in reliance upon and in conformity with information
relating to any Underwriter furnished to the Company by the Representatives in writing expressly for use in the Registration Statement, any preliminary prospectus, the Time of Sale Prospectus, any such free writing prospectus, any Marketing
Material, any Section&nbsp;5(d) Written Communication or the Prospectus (or any amendment or supplement thereto), it being understood and agreed that the only such information consists of the information described in Section&nbsp;9(b) below. The
indemnity agreement set forth in this Section&nbsp;9(a) shall be in addition to any liabilities that the Company may otherwise have. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B><I>Indemnification of the Company, its Directors and Officers</I></B>. Each Underwriter agrees, severally and not jointly, to
indemnify and hold harmless the Company, each of its directors, each of its officers who signed the Registration Statement and each person, if any, who controls the Company within the meaning of the Securities Act or the Exchange Act, against any
loss, claim, damage, liability or expense, as incurred, to which the Company, or any such director, officer or controlling person may become subject, under the Securities Act, the Exchange Act, or other federal or state statutory law or regulation,
or at common law or otherwise (including in settlement of any litigation, if such settlement is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
effected with the written consent of such Underwriter), insofar as such loss, claim, damage, liability or expense (or actions in respect thereof as contemplated below) arises out of or is based
upon (i)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, or any amendment thereto, or any omission or alleged omission to state therein a material fact required to be stated therein
or necessary to make the statements therein not misleading or (ii)&nbsp;any untrue statement or alleged untrue statement of a material fact included in any preliminary prospectus, the Time of Sale Prospectus, any free writing prospectus that the
Company has used, referred to or filed, or is required to file, pursuant to Rule 433 of the Securities Act, any Section&nbsp;5(d) Written Communication or the Prospectus (or any such amendment or supplement) or the omission or alleged omission to
state therein a material fact necessary in order to make the statements, in the light of the circumstances under which they were made, not misleading, in each case to the extent, but only to the extent, that such untrue statement or alleged untrue
statement or omission or alleged omission was made in the Registration Statement, such preliminary prospectus, the Time of Sale Prospectus, such free writing prospectus, any Section&nbsp;5(d) Written Communication or the Prospectus (or any such
amendment or supplement), in reliance upon and in conformity with information relating to such Underwriter furnished to the Company by the Representatives in writing expressly for use therein; and to reimburse the Company, or any such director,
officer or controlling person for any and all expenses (including the fees and disbursements of counsel) as such expenses are incurred by the Company, or any such director, officer or controlling person in connection with investigating, defending,
settling, compromising or paying any such loss, claim, damage, liability, expense or action. The Company hereby acknowledges that the only information that the Representatives has furnished to the Company expressly for use in the Registration
Statement, any preliminary prospectus, the Time of Sale Prospectus, any free writing prospectus that the Company has filed, or is required to file, pursuant to Rule 433(d) of the Securities Act, any Section&nbsp;5(d) Written Communication or the
Prospectus (or any amendment or supplement to the foregoing) are the statements set forth in the paragraphs under the caption &#147;Stabilization&#148; in the &#147;Underwriting&#148; section of the Preliminary Prospectus Supplement and the Final
Prospectus Supplement. The indemnity agreement set forth in this Section&nbsp;9(b) shall be in addition to any liabilities that each Underwriter may otherwise have. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B><I>Notifications and Other Indemnification Procedures</I></B><B>.</B> Promptly after receipt by an indemnified party under this
Section&nbsp;9 of notice of the commencement of any action, such indemnified party will, if a claim in respect thereof is to be made against an indemnifying party under this Section&nbsp;9, notify the indemnifying party in writing of the
commencement thereof, but the omission to so notify the indemnifying party will not relieve the indemnifying party from any liability which it may have to any indemnified party to the extent the indemnifying party is not materially prejudiced as a
proximate result of such failure and shall not in any event relieve the indemnifying party from any liability that it may have otherwise than on account of this indemnity agreement. In case any such action is brought against any indemnified party
and such indemnified party seeks or intends to seek indemnity from an indemnifying party, the indemnifying party will be entitled to participate in, and, to the extent that it shall elect, jointly with all other indemnifying parties similarly
notified, by written notice delivered to the indemnified party promptly after receiving the aforesaid notice from such indemnified party, to assume the defense thereof with counsel reasonably satisfactory to such indemnified party; <I>provided,
however</I>, that if the defendants in any such action include both the indemnified party and the indemnifying party and the indemnified party shall have reasonably concluded that a conflict may arise between the positions of the indemnifying party
and the indemnified party in conducting the defense of any such action or that there may be legal defenses available to it and/or other indemnified parties which are different from or additional to those available to the indemnifying party, the
indemnified party or parties shall have the right to select separate counsel to assume such legal defenses and to otherwise participate in the defense of such action on behalf of such indemnified party or parties. Upon receipt of notice from the
indemnifying party to such indemnified party of such indemnifying party&#146;s election to so assume the defense of such action and approval by the indemnified party of counsel, the indemnifying party will not be liable to such indemnified party
under this Section&nbsp;9 for any legal or other expenses subsequently incurred by such indemnified party in connection </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with the defense thereof unless (i)&nbsp;the indemnified party shall have employed separate counsel in accordance with the proviso to the preceding sentence (it being understood, however, that
the indemnifying party shall not be liable for the fees and expenses of more than one separate counsel (together with local counsel), representing the indemnified parties who are parties to such action), which counsel (together with any local
counsel) for the indemnified parties shall be selected by the Representatives (in the case of counsel for the indemnified parties referred to in Section&nbsp;9(a) above) or by the Company (in the case of counsel for the indemnified parties referred
to in Section&nbsp;9(b) above)) or (ii)&nbsp;the indemnifying party shall not have employed counsel satisfactory to the indemnified party to represent the indemnified party within a reasonable time after notice of commencement of the action or
(iii)&nbsp;the indemnifying party has authorized in writing the employment of counsel for the indemnified party at the expense of the indemnifying party, in each of which cases the fees and expenses of counsel shall be at the expense of the
indemnifying party and shall be paid as they are incurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B><I>Settlements</I></B><B>.</B> The indemnifying party under this
Section&nbsp;9 shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with such consent or if there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify the
indemnified party against any loss, claim, damage, liability or expense by reason of such settlement or judgment. Notwithstanding the foregoing sentence, if at any time an indemnified party shall have requested an indemnifying party to reimburse the
indemnified party for fees and expenses of counsel as contemplated by Section&nbsp;9(c) hereof, the indemnifying party shall be liable for any settlement of any proceeding effected without its written consent if (i)&nbsp;such settlement is entered
into more than 30&nbsp;days after receipt by such indemnifying party of the aforesaid request and (ii)&nbsp;such indemnifying party shall not have reimbursed the indemnified party in accordance with such request prior to the date of such settlement.
No indemnifying party shall, without the prior written consent of the indemnified party, effect any settlement, compromise or consent to the entry of judgment in any pending or threatened action, suit or proceeding in respect of which any
indemnified party is or could have been a party and indemnity was or could have been sought hereunder by such indemnified party, unless such settlement, compromise or consent includes an unconditional release of such indemnified party from all
liability on claims that are the subject matter of such action, suit or proceeding and does not include an admission of fault or culpability or a failure to act by or on behalf of such indemnified party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;10.</B> <B>Contribution</B>. If the indemnification provided for in Section&nbsp;9 is for any reason held to be
unavailable to or otherwise insufficient to hold harmless an indemnified party in respect of any losses, claims, damages, liabilities or expenses referred to therein, then each indemnifying party shall contribute to the aggregate amount paid or
payable by such indemnified party, as incurred, as a result of any losses, claims, damages, liabilities or expenses referred to therein (i)&nbsp;in such proportion as is appropriate to reflect the relative benefits received by the Company, on the
one hand, and the Underwriters, on the other hand, from the offering of the Offered Shares pursuant to this Agreement or (ii)&nbsp;if the allocation provided by clause&nbsp;(i) above is not permitted by applicable law, in such proportion as is
appropriate to reflect not only the relative benefits referred to in clause&nbsp;(i) above but also the relative fault of the Company, on the one hand, and the Underwriters, on the other hand, in connection with the statements or omissions which
resulted in such losses, claims, damages, liabilities or expenses, as well as any other relevant equitable considerations. The relative benefits received by the Company, on the one hand, and the Underwriters, on the other hand, in connection with
the offering of the Offered Shares pursuant to this Agreement shall be deemed to be in the same respective proportions as the total proceeds from the offering of the Offered Shares pursuant to this Agreement (before deducting expenses) received by
the Company, and the total underwriting discounts and commissions received by the Underwriters, in each case as set forth on the front cover page of the Prospectus, bear to the aggregate initial public offering price of the Offered Shares as set
forth on such cover. The relative fault of the Company, on the one hand, and the Underwriters, on the other hand, shall be determined by reference to, among other things, whether any such untrue or alleged untrue statement of a material fact or
omission or alleged omission to state a material fact relates to information supplied by the Company, on the one hand, or the Underwriters, on the other hand, and the parties&#146; relative intent, knowledge, access to information and opportunity to
correct or prevent such statement or omission. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amount paid or payable by a party as a result of the losses, claims, damages,
liabilities and expenses referred to above shall be deemed to include, subject to the limitations set forth in Section&nbsp;9(c), any legal or other fees or expenses reasonably incurred by such party in connection with investigating or defending any
action or claim. The provisions set forth in Section&nbsp;9(c) with respect to notice of commencement of any action shall apply if a claim for contribution is to be made under this Section&nbsp;10; <I>provided, however,</I> that no additional notice
shall be required with respect to any action for which notice has been given under Section&nbsp;9(c) for purposes of indemnification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company and the Underwriters agree that it would not be just and equitable if contribution pursuant to this Section&nbsp;10 were determined by pro rata allocation (even if the Underwriters were treated as one entity for such purpose) or by any other
method of allocation which does not take account of the equitable considerations referred to in this Section&nbsp;10. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the
provisions of this Section&nbsp;10, no Underwriter shall be required to contribute any amount in excess of the underwriting discounts and commissions received by such Underwriter in connection with the Offered Shares underwritten by it and
distributed to the public. No person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation.
The Underwriters&#146; obligations to contribute pursuant to this Section&nbsp;10 are several, and not joint, in proportion to their respective underwriting commitments as set forth opposite their respective names on <U>Schedule A</U>. For purposes
of this Section&nbsp;10, each affiliate, director, officer, employee and agent of an Underwriter and each person, if any, who controls an Underwriter within the meaning of the Securities Act or the Exchange Act shall have the same rights to
contribution as such Underwriter, and each director of the Company, each officer of the Company who signed the Registration Statement, and each person, if any, who controls the Company within the meaning of the Securities Act and the Exchange Act
shall have the same rights to contribution as the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;11.</B> <B>Default of One or More of the Several
Underwriters</B><I>.</I> If, on the First Closing Date or any Option Closing Date any one or more of the several Underwriters shall fail or refuse to purchase Offered Shares that it or they have agreed to purchase hereunder on such date, and the
aggregate number of Offered Shares which such defaulting Underwriter or Underwriters agreed but failed or refused to purchase does not exceed 10% of the aggregate number of the Offered Shares to be purchased on such date, the Representatives may
make arrangements satisfactory to the Company for the purchase of such Offered Shares by other persons, including any of the Underwriters, but if no such arrangements are made by such date, the other Underwriters shall be obligated, severally and
not jointly, in the proportions that the number of Firm Shares set forth opposite their respective names on <U>Schedule</U><B> A</B> bears to the aggregate number of Firm Shares set forth opposite the names of all such
<FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters, or in such other proportions as may be specified by the Representatives with the consent of the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters, to purchase the
Offered Shares which such defaulting Underwriter or Underwriters agreed but failed or refused to purchase on such date. If, on the First Closing Date or any Option Closing Date any one or more of the Underwriters shall fail or refuse to purchase
Offered Shares and the aggregate number of Offered Shares with respect to which such default occurs exceeds 10% of the aggregate number of Offered Shares to be purchased on such date, and arrangements satisfactory to the Representatives and the
Company for the purchase of such Offered Shares are not made within 48 hours after such default, this Agreement shall terminate without liability of any party to any other party except that the provisions of Section&nbsp;4, Section&nbsp;7,
Section&nbsp;9 and Section&nbsp;10 shall at all times be effective and shall survive such termination. In any such case either the Representatives or the Company shall have the right to postpone the First Closing Date or the applicable Option
Closing Date, as the case may be, but in no event for longer than seven days in order that the required changes, if any, to the Registration Statement and the Prospectus or any other documents or arrangements may be effected. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used in this Agreement, the term &#147;<B>Underwriter</B>&#148; shall be deemed to
include any person substituted for a defaulting Underwriter under this Section&nbsp;11. Any action taken under this Section&nbsp;11 shall not relieve any defaulting Underwriter from liability in respect of any default of such Underwriter under this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;12.</B> <B>Termination of this Agreement</B><I>.</I> Prior to the purchase of the Firm Shares by
the Underwriters on the First Closing Date, this Agreement may be terminated by the Representatives by notice given to the Company if at any time: (i)&nbsp;trading or quotation in any of the Company&#146;s securities shall have been suspended or
limited by the Commission or by the NASDAQ, or trading in securities generally on either the NASDAQ or the NYSE shall have been suspended or limited, or minimum or maximum prices shall have been generally established on any of such stock exchanges;
(ii)&nbsp;a general banking moratorium shall have been declared by any of federal, New York, or California authorities; (iii)&nbsp;there shall have occurred any outbreak or escalation of national or international hostilities or any crisis or
calamity, or any change in the United States or international financial markets, or any substantial change or development involving a prospective substantial change in United States&#146; or international political, financial or economic conditions,
as in the judgment of the Representatives is material and adverse and makes it impracticable to market the Offered Shares in the manner and on the terms described in the Time of Sale Prospectus or the Prospectus or to enforce contracts for the sale
of securities; (iv)&nbsp;in the judgment of the Representatives there shall have occurred any Material Adverse Change; or (v)&nbsp;the Company shall have sustained a loss by strike, fire, flood, earthquake, accident or other calamity of such
character as in the judgment of the Representatives may interfere materially with the conduct of the business and operations of the Company regardless of whether or not such loss shall have been insured. Any termination pursuant to this
Section&nbsp;12 shall be without liability on the part of (a)&nbsp;the Company to any Underwriter, except that the Company shall be obligated to reimburse the expenses of the Representatives and the Underwriters pursuant to Section&nbsp;4 or
Section&nbsp;7&nbsp;hereof or (b)&nbsp;any Underwriter to the Company; <I>provided, however,</I> that the provisions of Section&nbsp;9 and Section&nbsp;10 shall at all times be effective and shall survive such termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;13.</B> <B>No Advisory or Fiduciary Relationship. </B>The Company acknowledges and agrees that (a)&nbsp;the
purchase and sale of the Offered Shares pursuant to this Agreement, including the determination of the public offering price of the Offered Shares and any related discounts and commissions, is an
<FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> commercial transaction between the Company, on the one hand, and the several Underwriters, on the other hand, (b)&nbsp;in connection with the offering contemplated hereby and the process
leading to such transaction, each Underwriter is and has been acting solely as a principal and is not the agent or fiduciary of the Company, or its stockholders, creditors, employees or any other party, (c)&nbsp;no Underwriter has assumed or will
assume an advisory or fiduciary responsibility in favor of the Company with respect to the offering contemplated hereby or the process leading thereto (irrespective of whether such Underwriter has advised or is currently advising the Company on
other matters) and no Underwriter has any obligation to the Company with respect to the offering contemplated hereby except the obligations expressly set forth in this Agreement, (d)&nbsp;the Underwriters and their respective affiliates may be
engaged in a broad range of transactions that involve interests that differ from those of the Company, and (e)&nbsp;the Underwriters have not provided any legal, accounting, regulatory or tax advice with respect to the offering contemplated hereby
and the Company has consulted its own legal, accounting, regulatory and tax advisors to the extent it deemed appropriate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;14.</B> <B>Representations and Indemnities to Survive
Delivery</B><I>.</I> The respective indemnities, agreements, representations, warranties and other statements of the Company, of its officers and of the several Underwriters set forth in or made pursuant to this Agreement will remain in full force
and effect, regardless of any investigation made by or on behalf of any Underwriter or the Company or any of its or their partners, officers or directors or any controlling person, as the case may be, and, anything herein to the contrary
notwithstanding, will survive delivery of and payment for the Offered Shares sold hereunder and any termination of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;15.</B> <B>Notices</B>. All communications hereunder shall be in writing and shall be mailed, hand delivered or
telecopied and confirmed to the parties hereto as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="57%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">If to the Representatives:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jefferies LLC</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">520 Madison Avenue</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10022</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Attention: General Counsel</P></TD></TR>

<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stifel, Nicolaus&nbsp;&amp; Company, Incorporated</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">787 7th Avenue</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11th Floor</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">New York, New York 10019</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Wells Fargo Securities, LLC</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">500 West 33rd
Street</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10001</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Attention: Equity Syndicate
Department</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">with a copy to:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goodwin Procter LLP</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The New York Times
Building</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">620 Eighth Avenue</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10018</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Attention: Thomas Levato</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">If to the Company:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MEI Pharma, Inc.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11455 El Camino Real, Suite
250</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Diego, CA 92130</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Attention: Chief Executive
Officer</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">with a copy to:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Morgan, Lewis&nbsp;&amp; Bockius LLP</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">101 Park
Ave.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10178</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Attention: Steven
Navarro</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any party hereto may change the address for receipt of communications by giving written notice to the others. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;16.</B> <B>Successors</B><I>.</I> This Agreement will inure to the benefit of and be binding upon the parties
hereto, including any substitute Underwriters pursuant to Section&nbsp;11 hereof, and to the benefit of the affiliates, directors, officers, employees, agents and controlling persons referred to in Section&nbsp;9 and Section&nbsp;10, and in each
case their respective successors, and no other person will have any right or obligation hereunder. The term &#147;<B>successors</B>&#148; shall not include any purchaser of the Offered Shares as such from any of the Underwriters merely by reason of
such purchase. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;17.</B> <B>Partial Unenforceability</B>. The invalidity or
unenforceability of any section, paragraph or provision of this Agreement shall not affect the validity or enforceability of any other section, paragraph or provision hereof. If any section, paragraph or provision of this Agreement is for any reason
determined to be invalid or unenforceable, there shall be deemed to be made such minor changes (and only such minor changes) as are necessary to make it valid and enforceable.<B><I> </I></B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;18. Recognition of the U.S. Special Resolution Regimes.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> In the event that any Underwriter that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution Regime,
the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and
any such interest and obligation, were governed by the laws of the United States or a state of the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> In the event
that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are
permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of this Agreement, (A) &#147;<B><I>BHC Act Affiliate</I></B>&#148; has the meaning assigned to the term &#147;affiliate&#148; in, and shall be
interpreted in accordance with, 12 U.S.C. &#167; 1841(k); (B) &#147;<B>Covered Entity</B>&#148; means any of the following: (i)&nbsp;a &#147;covered entity&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167;
252.82(b); (ii) a &#147;covered bank&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 47.3(b); or (iii)&nbsp;a &#147;covered FSI&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R.
&#167; 382.2(b); (C) &#147;<B><I>Default Right</I></B>&#148; has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &#167;&#167; 252.81, 47.2 or 382.1, as applicable; and (D) &#147;<B><I>U.S. Special
Resolution Regime</I></B>&#148; means each of (i)&nbsp;the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii)&nbsp;Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations
promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;19.</B> <B>Governing Law Provisions</B><I>.</I> This Agreement shall be governed by
and construed in accordance with the internal laws of the State of New York applicable to agreements made and to be performed in such state. Any legal suit, action or proceeding arising out of or based upon this Agreement or the transactions
contemplated hereby (&#147;<B>Related Proceedings</B>&#148;) may be instituted in the federal courts of the United States of America located in the Borough of Manhattan in the City of New York or the courts of the State of New York in each case
located in the Borough of Manhattan in the City of New York (collectively, the &#147;<B>Specified Courts</B>&#148;), and each party irrevocably submits to the exclusive jurisdiction (except for proceedings instituted in regard to the enforcement of
a judgment of any such court (a &#147;<B>Related Judgment</B>&#148;), as to which such jurisdiction is <FONT STYLE="white-space:nowrap">non-exclusive)</FONT> of such courts in any such suit, action or proceeding. Service of any process, summons,
notice or document by mail to such party&#146;s address set forth above shall be effective service of process for any suit, action or other proceeding brought in any such court. The parties irrevocably and unconditionally waive any objection to the
laying of venue of any suit, action or other proceeding in the Specified Courts and irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such suit, action or other proceeding brought in any such court has
been brought in an inconvenient forum. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;20.</B> <B>General Provisions</B><B>.</B> This Agreement constitutes
the entire agreement of the parties to this Agreement and supersedes all prior written or oral and all contemporaneous oral agreements, understandings and negotiations with respect to the subject matter hereof. This Agreement may be executed in two
or more counterparts, each one of which shall be an original, with the same effect </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
as if the signatures thereto and hereto were upon the same instrument. Counterparts may be delivered via facsimile, electronic mail (including any electronic signature covered by the U.S. federal
ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and
validly delivered and be valid and effective for all purposes. This Agreement may not be amended or modified unless in writing by all of the parties hereto, and no condition herein (express or implied) may be waived unless waived in writing by each
party whom the condition is meant to benefit. The section headings herein are for the convenience of the parties only and shall not affect the construction or interpretation of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of the parties hereto acknowledges that it is a sophisticated business person who was adequately represented by counsel during
negotiations regarding the provisions hereof, including, without limitation, the indemnification provisions of Section&nbsp;9 and the contribution provisions of Section&nbsp;10, and is fully informed regarding said provisions. Each of the parties
hereto further acknowledges that the provisions of Section&nbsp;9 and&nbsp;Section 10 hereof fairly allocate the risks in light of the ability of the parties to investigate the Company, its affairs and its business in order to assure that adequate
disclosure has been made in the Registration Statement, any preliminary prospectus, the Time of Sale Prospectus, each free writing prospectus and the Prospectus (and any amendments and supplements to the foregoing), as contemplated by the Securities
Act and the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>SIGNATURE PAGE FOLLOWS</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g257552g33s26.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the foregoing is in accordance with your understanding of our agreement, kindly sign and return to the
Company the enclosed copies hereof, whereupon this instrument, along with all counterparts hereof, shall become a binding agreement in accordance with its terms. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Very truly yours,</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MEI PHARMA, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Daniel P. Gold</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: Daniel P. Gold</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title: CEO</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to
Underwriting Agreement] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing Underwriting Agreement is hereby confirmed and accepted by the Representatives
in New York, New York as of the date first above written. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>JEFFERIES LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>STIFEL, NICOLAUS&nbsp;&amp; COMPANY, INCORPORATED </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>WELLS FARGO SECURITIES, LLC </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Acting individually and as
Representatives </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">of the several Underwriters named in </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">the
attached <U>Schedule A</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>JEFFERIES LLC </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Michael Brinkman</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: Michael Brinkman</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title: Managing Director, Joint US Head of Biopharmaceuticals</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>STIFEL, NICOLAUS&nbsp;&amp; COMPANY, INCORPORATED </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Nathan Thompson</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: Nathan Thompson</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title: Director</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>WELLS FARGO SECURITIES, LLC </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ David Bohn</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: David Bohn</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title: Managing Director</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Schedule A </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Underwriters</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Firm Shares</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>to&nbsp;be&nbsp;Purchased</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jefferies LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,087,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stifel, Nicolaus&nbsp;&amp; Company, Incorporated</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,337,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wells Fargo Securities, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,800,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">LifeSci Capital, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,400,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">H.C. Wainwright&nbsp;&amp; Co.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">875,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Schedule B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Free Writing Prospectuses Included in the Time of Sale Prospectus </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>None. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Schedule C </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Pricing Terms </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company is selling 17,500,000 Shares. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company has granted an option to the Underwriters, severally and not jointly, to purchase up to 2,625,000
additional Shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The public offer price per Share shall be $2.600. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Underwriters&#146; discount shall be 6% </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit C </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>L<SMALL>OCK</SMALL><FONT STYLE="white-space:nowrap">-</FONT><SMALL>UP</SMALL> A<SMALL>GREEMENT</SMALL> </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">___, 2021 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jefferies LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stifel, Nicolaus&nbsp;&amp; Company, Incorporated </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Wells Fargo
Securities, LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As Representatives of the Several Underwriters </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Jefferies LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">520 Madison Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Stifel, Nicolaus&nbsp;&amp;
Company, Incorporated </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">787 7th Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11th Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10019 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Wells Fargo Securities, LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">500 West 33rd Street </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">14th Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10001 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">RE:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">MEI Pharma, Inc. (the &#147;<B>Company</B>&#148;) </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies&nbsp;&amp; Gentlemen: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned is an officer,
director and/or owner of shares of common stock, par value $0.00000002 per share, of the Company (&#147;<B>Shares</B>&#148;), or of securities convertible into or exchangeable or exercisable for Shares. The Company proposes to conduct a public
offering of Shares (the &#147;<B>Offering</B>&#148;) for which Jefferies LLC (&#147;<B>Jefferies</B>&#148;), Stifel, Nicolaus&nbsp;&amp; Company, Incorporated (&#147;<B>Stifel</B>&#148;) and Wells Fargo Securities, LLC (&#147;<B>Wells
Fargo</B>&#148;) will act as the representatives of the underwriters. The undersigned recognizes that the Offering will benefit each of the Company and the undersigned. The undersigned acknowledges that the underwriters are relying on the
representations and agreements of the undersigned contained in this letter agreement in conducting the Offering and, at a subsequent date, in entering into an underwriting agreement (the &#147;<B>Underwriting Agreement</B>&#148;) and other
underwriting arrangements with the Company with respect to the Offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Annex A sets forth definitions for capitalized terms used in this letter
agreement that are not defined in the body of this letter agreement. Those definitions are a part of this letter agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In consideration of the
foregoing, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the undersigned hereby agrees that, during the <FONT STYLE="white-space:nowrap">Lock-up</FONT> Period, the undersigned will not
(and will cause any Family Member not to), without the prior written consent of Jefferies and Stifel, which may withhold their consent in their sole discretion: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Sell or Offer to Sell any Shares or Related Securities currently or hereafter owned either of record or
beneficially (as defined in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the Exchange Act) by the undersigned or such Family Member, </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enter into any Swap, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make any demand for, or exercise any right with respect to, the registration under the Securities Act of the
offer and sale of any Shares or Related Securities, or cause to be filed a registration statement, prospectus or prospectus supplement (or an amendment or supplement thereto) with respect to any such registration, or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">publicly announce any intention to do any of the foregoing. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing will not apply to the registration of the offer and sale of the Shares, and the sale of the Shares to the underwriters, in each case as
contemplated by the Underwriting Agreement. In addition, the foregoing restrictions shall not apply to the transfer of Shares or Related Securities by gift to a Family Member or to a trust whose beneficiaries consist exclusively of one or more of
the undersigned and/or a Family Member or to any person by will or intestate succession; <I>provided, however</I>, that in any such case, it shall be a condition to such transfer that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each transferee executes and delivers to Jefferies and Stifel an agreement in form and substance satisfactory to
Jefferies and Stifel stating that such transferee is receiving and holding such Shares and/or Related Securities subject to the provisions of this letter agreement and agrees not to Sell or Offer to Sell such Shares and/or Related Securities, engage
in any Swap or engage in any other activities restricted under this letter agreement except in accordance with this letter agreement (as if such transferee had been an original signatory hereto), and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prior to the expiration of the <FONT STYLE="white-space:nowrap">Lock-up</FONT> Period, no public disclosure or
filing under the Exchange Act by any party to the transfer (donor, donee, transferor or transferee) shall be required, or made voluntarily, reporting a reduction in beneficial ownership of Shares in connection with such transfer.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing restrictions shall not apply to (i)&nbsp;the exercise of options to purchase Shares expiring during the <FONT
STYLE="white-space:nowrap">Lock-up</FONT> Period (provided that, unless otherwise provided herein, such Shares received upon exercise shall also be subject to this letter agreement) and the disposition to the Company of Shares acquired upon the
exercise of such stock options to the extent necessary to pay the exercise price and related withholding taxes provided, that, if the undersigned is required to file a report under the Exchange Act, reporting a reduction in beneficial ownership of
Shares during the term of this letter agreement related to such disposition of Shares to the Company by the undersigned solely to pay the exercise price and satisfy tax withholding obligations, the undersigned shall include a statement in such
report to the effect that the filing relates to the net exercise and satisfaction of the tax withholding obligations of the undersigned in connection with such exercise or vesting; and (ii)&nbsp;the transfer of Shares or options pursuant to a
domestic relations order; provided that, any such order provides that the Shares transferred are subject to this letter agreement and the transferee agrees to be bound to this letter agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned also agrees and consents to the entry of stop transfer instructions with the Company&#146;s transfer agent and registrar against the transfer
of Shares or Related Securities held by the undersigned and the undersigned&#146;s Family Members, if any, except in compliance with the foregoing restrictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With respect to the Offering only, the undersigned waives any registration rights relating to registration under the Securities Act of the offer and sale of
any Shares and/or any Related Securities owned either of record or beneficially by the undersigned, including any rights to receive notice of the Offering. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned confirms that the undersigned has not, and has no knowledge that any Family Member has,
directly or indirectly, taken any action designed to or that might reasonably be expected to cause or result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale of the Shares. The undersigned will
not, and will cause any Family Member not to take, directly or indirectly, any such action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Whether or not the Offering occurs as currently contemplated
or at all depends on market conditions and other factors. The Offering will only be made pursuant to the Underwriting Agreement, the terms of which are subject to negotiation between the Company and the underwriters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned hereby represents and warrants that the undersigned has full power, capacity and authority to enter into this letter agreement. This letter
agreement is irrevocable and will be binding on the undersigned and the successors, heirs, personal representatives and assigns of the undersigned. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This
letter agreement shall be governed by, and construed in accordance with, the laws of the State of New York. This agreement shall lapse and become null and void (i)&nbsp;upon written notice from the Company to Jefferies, Stifel and Wells Fargo that
the Company does not intend to proceed with the Offering or wishes to terminate the engagement of Jefferies, Stifel and Wells Fargo prior to the Offering or (ii)&nbsp;if the Offering shall not have occurred on or before December&nbsp;31, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature page follows] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-TOP:1px solid #000000">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printed Name of Person Signing</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>(Indicate capacity of person signing if signing as custodian or trustee, or on behalf of an entity)</I></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature page to <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>ANNEX A </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>C<SMALL>ERTAIN</SMALL> D<SMALL>EFINED</SMALL> T<SMALL>ERMS</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>U<SMALL>SED</SMALL> <SMALL>IN</SMALL> L<SMALL>OCK</SMALL><FONT STYLE="white-space:nowrap">-</FONT><SMALL>UP</SMALL>
A<SMALL>GREEMENT</SMALL> </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of the letter agreement to which this Annex A is attached and of which it is made a part: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<B>Call Equivalent Position</B>&#148;<B> </B>shall have the meaning set forth in Rule <FONT
STYLE="white-space:nowrap">16a-1(b)</FONT> under the Exchange Act. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<B>Exchange Act</B>&#148;<B> </B>shall mean the Securities Exchange Act of 1934, as amended.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<B>Family Member</B>&#148; shall mean the spouse of the undersigned, an immediate family member of the
undersigned or an immediate family member of the undersigned&#146;s spouse, in each case living in the undersigned&#146;s household or whose principal residence is the undersigned&#146;s household (regardless of whether such spouse or family member
may at the time be living elsewhere due to educational activities, health care treatment, military service, temporary internship or employment or otherwise). &#147;<B>Immediate family member</B>&#148; as used above shall have the meaning set forth
in Rule <FONT STYLE="white-space:nowrap">16a-1(e)</FONT> under the Exchange Act. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<B><FONT STYLE="white-space:nowrap">Lock-up</FONT> Period</B>&#148; shall mean the period beginning on the
date hereof and continuing through the close of trading on the date that is 90 days after the date of the Prospectus (as defined in the Underwriting Agreement). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<B>Put Equivalent Position</B>&#148; shall have the meaning set forth in Rule <FONT
STYLE="white-space:nowrap">16a-1(h)</FONT> under the Exchange Act. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<B>Related Securities</B>&#148; shall mean any options or warrants or other rights to acquire Shares or any
securities exchangeable or exercisable for or convertible into Shares, or to acquire other securities or rights ultimately exchangeable or exercisable for or convertible into Shares. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<B>Securities Act</B>&#148; shall mean the Securities Act of 1933, as amended. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<B>Sell or Offer to Sell</B>&#148; shall mean to: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#150;&nbsp;&nbsp;&nbsp;&nbsp;sell, offer to sell, contract to sell or lend, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#150;&nbsp;&nbsp;&nbsp;&nbsp;effect any short sale or establish or increase a Put Equivalent Position or
liquidate or decrease any Call Equivalent Position </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#150;&nbsp;&nbsp;&nbsp;&nbsp;pledge, hypothecate or grant any security interest in, or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#150;&nbsp;&nbsp;&nbsp;&nbsp;in any other way transfer or dispose of, </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">in each case whether effected directly or indirectly. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<B>Swap</B>&#148; shall mean any swap, hedge or similar arrangement or agreement that transfers, in whole
or in part, the economic risk of ownership of Shares or Related Securities, regardless of whether any such transaction is to be settled in securities, in cash or otherwise. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Capitalized terms not defined in this Annex A shall have the meanings given to them in the body of this letter agreement. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>d257552dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g257552g1206102836962.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">December&nbsp;6, 2021 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MEI Pharma, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11455 El Camino Real, Suite 250 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Diego, California 92130 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>MEI Pharma, Inc. &#150; Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT>
(Registration Statement No.</U><U></U><U><FONT STYLE="white-space:nowrap">&nbsp;333-238056</FONT></U><U>)</U> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have acted as counsel to MEI Pharma, Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;), in connection with (i)&nbsp;the offering by the
Company of 20,125,000 shares (the &#147;<U>Firm Shares</U>&#148;) of its common stock, $0.00000002 par value per share (the &#147;<U>Common Stock</U>), which includes 2,625,000 shares (the &#147;<U>Option Shares</U>&#148; and together with the Firm
Shares, the &#147;<U>Shares</U>&#148;) of Common Stock with respect to which the underwriters were granted an option to purchase, pursuant to an Underwriting Agreement (the &#147;<U>Underwriting Agreement</U>&#148;), dated as of December&nbsp;1,
2021, between the Company, Jefferies LLC, Stifel, Nicolaus&nbsp;&amp; Company, Incorporated, and Wells Fargo Securities, LLC as representatives of the several underwriters named therein, (ii)&nbsp;the filing by the Company of the above-referenced
Registration Statement (the &#147;<U>Registration Statement</U>&#148;) under the Securities Act of 1933, as amended (the &#147;<U>Act</U>&#148;), with the Securities and Exchange Commission (the &#147;<U>SEC</U>&#148;), (iii)&nbsp;the filing by the
Company of the preliminary prospectus supplement relating to the Shares dated November&nbsp;30, 2021, including the accompanying base prospectus dated May&nbsp;18, 2020, which was filed by the Company with the SEC on November&nbsp;30, 2021 pursuant
to Rule 424(b)(5) promulgated under the Act (the &#147;<U>Preliminary Prospectus Supplement</U>&#148;) and (iv)&nbsp;the filing by the Company of the prospectus supplement relating to the Shares dated December&nbsp;1, 2021, including the
accompanying base prospectus dated May&nbsp;18, 2020, which was filed by the Company with the SEC on December&nbsp;2, 2021 pursuant to Rule 424(b)(5) promulgated under the Act (the &#147;<U>Prospectus Supplement</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with this opinion letter, we have examined originals, or copies certified or otherwise identified to our satisfaction, of the Registration
Statement, the Preliminary Prospectus Supplement, the Prospectus Supplement, the Underwriting Agreement, the Amended and Restated Certificate of Incorporation, and the Third Amended and Restated Bylaws of the Company and such other documents,
records and other instruments as we have deemed appropriate for purposes of the opinions set forth herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have assumed the genuineness of all
signatures, the legal capacity of all natural persons, the authenticity of the documents submitted to us as originals, the conformity with the originals of all documents submitted to us as certified, facsimile or photostatic copies and the
authenticity of the originals of all documents submitted to us as copies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based upon the foregoing, and subject to the qualifications, assumptions and
limitations stated herein, we are of the opinion that, when issued and paid for in accordance with the terms of the Underwriting Agreement, the Shares will be validly issued, fully paid and nonassessable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The opinions expressed herein are limited to the Delaware General Corporation Law and we express no opinion with respect to the laws of any other state or
jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to the use of this opinion as an exhibit to the Registration Statement and to the reference to us under the caption
&#147;Legal Matters&#148; in the Prospectus Supplement. In giving such consent, we do not hereby admit that we are acting within the category of persons whose consent is required under Section&nbsp;7 of the Act or the rules or regulations of the SEC
thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Very truly yours, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Morgan, Lewis &amp;
Bockius LLP </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>d257552dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MEI Pharma Announces Pricing of Public Offering of Common Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>San Diego </B>&#150; December&nbsp;1, 2021 &#150; MEI Pharma, Inc. (Nasdaq: MEIP), a late-stage pharmaceutical company focused on advancing new therapies
for cancer, announced today that it has priced the underwritten public offering of 17,500,000 shares of its common stock at $2.60 per share for total gross proceeds (before underwriting discount and commissions and estimated expenses) of
$45,500,000. In connection with the offering, the Company granted the underwriters a <FONT STYLE="white-space:nowrap">30-day</FONT> option to purchase up to an additional 2,625,000 shares of common stock offered in the public offering. The offering
is expected to close on December&nbsp;6, 2021, subject to the satisfaction of customary closing conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company plans to use the net proceeds of
the offering, together with other available funds, to progress its clinical development programs, prepare for and support the commercial launch of zandelisib, subject to receiving FDA marketing approval, and for other general corporate purposes.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jefferies, Stifel and Wells Fargo Securities are acting as joint book-running managers for the offering. LifeSci Capital and H.C. Wainwright&nbsp;&amp;
Co. are acting as <FONT STYLE="white-space:nowrap">co-managers</FONT> for the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The securities described above are being offered pursuant to a
&#147;shelf&#148; registration statement previously filed and declared effective by the Securities and Exchange Commission (SEC). The offering is being made only by means of a prospectus supplement and accompanying base prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When available, copies of the final prospectus supplement and accompanying base prospectus relating to the offering may be obtained from Jefferies LLC,
Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022 or by email at Prospectus_Department@Jefferies.com; Stifel, Nicolaus&nbsp;&amp; Company, Incorporated, Attention: Syndicate, One Montgomery Street,
Suite 3700, San Francisco, CA 94104, by telephone at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">415-364-2720</FONT></FONT> or by email at syndprospectus@stifel.com; or Wells Fargo Securities, LLC, Attention: Equity Syndicate
Department, 500 West 33rd Street, New York, New York 10001 at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">833-690-2713</FONT></FONT> or email a request to cmclientsupport@wellsfargo.com. An electronic copy of the final
prospectus supplement and accompanying base prospectus relating to the offering will also be available on the website of the SEC at www.sec.gov. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This
release does not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or
qualification under the securities laws of any such jurisdiction. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About MEI Pharma </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MEI Pharma, Inc. (Nasdaq: MEIP) is a late-stage pharmaceutical company focused on developing potential new therapies for cancer. MEI Pharma&#146;s portfolio of
drug candidates contains multiple clinical-stage assets, including zandelisib, currently in ongoing clinical trials which may support marketing approvals with the&nbsp;U.S.&nbsp;Food and Drug Administration and other regulatory authorities globally.
Each of MEI Pharma&#146;s pipeline candidates leverages a different mechanism of action with the objective of developing therapeutic options that are: (1)&nbsp;differentiated, (2) address unmet medical needs and (3)&nbsp;deliver improved benefit to
patients either as standalone treatments or in combination with other therapeutic options. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements</B><I>&nbsp;</I><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical studies and approved by the FDA as being safe and effective for the
intended use. Statements included in this press release that are not historical in nature are &#147;forward-looking statements&#148; within the meaning of the &#147;safe harbor&#148; provisions of the Private Securities Litigation Reform Act of
1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management&#146;s current expectations and are subject to a number of risks and uncertainties,
including, but not limited to, our failure to successfully commercialize our product candidates; the availability or appropriateness of utilizing the FDA&#146;s accelerated approval pathway for our product candidates; costs and delays in the
development and or FDA approval, or the failure to obtain such approval of our product candidates; final data from our <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and completed clinical trials may differ materially from reported
interim data from ongoing studies and trials; the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on our industry and individual companies, including on our counterparties, the supply chain, the execution of our clinical
development programs, our access to financing and the allocation of government resources; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the
development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual
property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any
additional required financing; technological changes; government regulation; changes in industry practice; and <FONT STYLE="white-space:nowrap">one-time</FONT> events. We do not intend to update any of these factors or to publicly announce the
results of any revisions to these forward-looking statements. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contacts: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">David A. Walsey </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tel: <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">858-369-7104</FONT></FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">investor@meipharma.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jason I. Spark </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Canale Communications for MEI </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tel: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">619-849-6005</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">jason.spark@canalecomm.com </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>meip-20211201.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20210621.2 -->
<!-- Creation date: 12/7/2021 3:11:05 AM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2020-01-31"
  xmlns:meip="http://www.meipharma.com/20211201"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"

  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.meipharma.com/20211201"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2020-01-31" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />

    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="meip-20211201_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="meip-20211201_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.meipharma.com//20211201/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>meip-20211201_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20210621.2 -->
<!-- Creation date: 12/7/2021 3:11:06 AM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>meip-20211201_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20210621.2 -->
<!-- Creation date: 12/7/2021 3:11:06 AM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.meipharma.com//20211201/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="meip-20211201.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com//20211201/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g257552g1206102836962.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g257552g1206102836962.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  H -H# 2(  A$! Q$!_\0
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M_L1B&VF !=A[_P!['O0!]%T5YCKOQ"U"_P#A,OC'POY:RQ.#<PRH'V ':X_
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MB-\7O$[,JEECG*DCI^_7I7HWPL^'-S\/H-4CN+Z*Z^V-&R^6I&W:&]?]ZH/
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MYTL2I!<1RK+!,PR$(X/X$$_I5KP)X4C\%^$K31DD662,L\TJC&]V.2?Y#\*
M/'/CI_R5+PM_URB_]'FO3?BAX*T_QMHMK:7-\EE>12DVDKG@L1RI'?('Z5G_
M ! ^&-UXR\6Z3K4.H0VZ6*(K1NI);;(6XQ]:O?$KX>2^/+:S,&JRV5Q9LS1#
MG82>YQR#[T >30^)_&WP@UZPTO7+E;[2I,;$+[P8P0"5/4$>E?2BL&4,.A&1
M7A>B_ ;49M;M[WQ5KOVZ"W8%8E9F+@'.TEN@KW7H,"@ HHHH **** "BBB@
MHHHH \%U[X/>,-,\17>K^$-?D;[6Y>02W!27DYPQZ-]?TJYX(^#6K1^*(O$O
MC/4%N[J!Q)'")#(6<?=+L>P[ >E%% 'MU%%% !1110 4444 %%%% !1110 4
2444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g257552g33s26.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g257552g33s26.jpg
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M P,# P,# P,# P,# P,# P,# P,#_\  $0@ ,@$S P$1  (1 0,1 ?_$ +<
M  $$ P$! 0$            '" D*!08+! (! P$!  (!!0$
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MST_*1T'!PK!W*S$S,/FT9$Q,6P04=/Y*3D7JJ#-@P9-DC*++*G(FFF43&$
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M0DQ.V&0C';A!2.9D;G=@;2MV^,C01%)?&7<?WZK%W02%2-EKYD+&6:J8L^(
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M[;"7/#'H4_-0C_D+>DDD@DFBBFFBBD0J:221"II))D*!2)IID "D(0H
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>d257552d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="meip-20211201.xsd" xlink:type="simple"/>
    <context id="duration_2021-12-01_to_2021-12-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001262104</identifier>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-01</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2021-12-01_to_2021-12-01">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2021-12-01_to_2021-12-01"
      id="Hidden_dei_EntityCentralIndexKey">0001262104</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2021-12-01_to_2021-12-01">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2021-12-01_to_2021-12-01">2021-12-01</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2021-12-01_to_2021-12-01">MEI Pharma, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2021-12-01_to_2021-12-01">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2021-12-01_to_2021-12-01">000-50484</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2021-12-01_to_2021-12-01">51-0407811</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2021-12-01_to_2021-12-01">11455 El Camino Real</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2021-12-01_to_2021-12-01">Suite 250</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2021-12-01_to_2021-12-01">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2021-12-01_to_2021-12-01">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2021-12-01_to_2021-12-01">92130</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2021-12-01_to_2021-12-01">(858)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2021-12-01_to_2021-12-01">369-7100</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2021-12-01_to_2021-12-01">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2021-12-01_to_2021-12-01">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2021-12-01_to_2021-12-01">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2021-12-01_to_2021-12-01">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2021-12-01_to_2021-12-01">Common stock, $0.00000002 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2021-12-01_to_2021-12-01">MEIP</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2021-12-01_to_2021-12-01">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2021-12-01_to_2021-12-01">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140095552949976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Dec. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001262104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec.  01,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MEI Pharma, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-50484<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">51-0407811<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">11455 El Camino Real<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(858)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">369-7100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common stock, $0.00000002 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MEIP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
MP8J&4R7_IZ%'!   W!   !@   !X;"]W;W)K<VAE971S+W-H965T,2YX;6R=
MF%USXC84AJ^WOT+#]**=(=@2G]D!9@@A6V8W61IH=Z:=7@A;@":VY<IR@'_?
M(YO8;-8<,\U%L(W.ZT='1Z\DAGNE7Y*=$(8<PB!*1HV=,?%'QTF\G0AYTE*Q
MB.";C=(A-W"KMTX2:\']+"@,'.:Z/2?D,FJ,A]FSA1X/56H"&8F%)DD:AEP?
M[T2@]J,&;;P]>);;G;$/G/$PYENQ%.:/>*'ASBE4?!F**)$J(EIL1HT)_7C'
MNC8@:_&G%/OD[)K8KJR5>K$W<W_4<"V1"(1GK 2'CU<Q%4%@E8#CWY-HHWBG
M#3R_?E-_R#H/G5GS1$Q5\$WZ9C=J#!K$%QN>!N99[7\3IPYE@)X*DNP_V>=M
M.VZ#>&EB5'@*!H)01ODG/YP2<1;0[ET(8*< EG'G+\HH[[GAXZ%6>Z)M:U"S
M%UE7LVB DY$=E:71\*V$.#.^5UX*23:$1SZ914::(YE'^6A#UH:.@9?8IHYW
M$KS+!=DE0>&UB$N;A+F,?A_N %L!R I ENFU+^A-U:O0Y._).C$:AO ?1+)=
M2+8SR<X%R0ETV,\Z_1#P;547\?@-#Q*!<'0*C@ZJ<TKW%$@T#R#MOCB0S^)8
M180KN:Y+68]1MX-@=0NL+BI6E,3J&(LJ%CQ\</,9@>@5$+WK(!9"2V5+TR=0
MX)4\-4JV(&GSIP\?:BJR7Z#UKQFV9[&5MB:!\8F'E6"XSN-L3A8[#C.M"6/O
MM1"T08$VN 8-U)2.E<ZF,%D:R!N9JA3*#*I-^96LN/#]#*&[+>ANKZ%[D($@
M3VFX%KH*!-> 2K_INIT!5NC4+<W/O89HQ0]D[D.UR8WT\J1=YJN1[-(;M^/V
M!Q0K-7IFS_0:PHGO:Y$DS;<+\@7:D:]1Y5#62%+:Z7;)+"!3#@N*@D+F <9:
M.C5E_Y]UM5>5K+CD,I50NZSK8H"E[U/<N-\#3NV=TF2E]M4K'2ZWY!&YEV*K
M,+AR,:!7K08%7#YM@6ZAU:N,O.JAQC6G$PRM7! H;NGOT18J,;!@_27CBW92
MHWC+:!L=TW*=H+B]9V,X@0WI911<X)=!=_ KAE*N"Q0W]"_*@ZPL=BK"_*U&
MI-V[O>E3%TU.N1Q0W+:_:6F,B" U89A&)V]+*JEPH;HM#RW7 (H;^%(%TI-&
M1EOR" 6NY7OS.?'@*G4\K%P"&.[7"RVR] B88?FN!S:'L./\NME4CU^-7BU9
M:?T,]^D?R.9)D@)9+2 N6PMXMC.O,6?AI=I./\K69"5-4#G]:D1L#V&]A8..
M]](D/[LM-_]C).::O/(@16%+[V>X6:\T]VW1+8_A6E667(T ;-<6&$EI] PW
MY2)MLX.WX]%67-P_U@@]39;WD]\QIM+AV54./PN%WMHL?0(%L[/E%_.H\D!2
M(WBQRIRSLZH]]S]R^\:$!&(#0FZK#[HZ/TKG-T;%V?%UK0P<AK/+G> P VP#
M^'ZCE'F[L2?BX@>-\7]02P,$%     @ P8J&4Y^@&_"Q @  X@P   T   !X
M;"]S='EL97,N>&ULW5=M:]LP$/XK0C]@;F)JXI$8MD!AL(U"\V%?E5AV!'KQ
M9+ES^NNGLVPG:75EW8>QS:')W3VZNT=W)YFN6W>2_.'(N2.]DKK=T*-SS?LD
M:0]'KEC[SC1<>Z0R5C'G55LG;6,Y*UMP4C)9WMQDB6)"TV*M.W6G7$L.IM-N
M0V]H4JPKH\^6E :#7\H4)X],;NB62;&W8EC+E)"G8%Z"X6"DL<1Y*GQ#%V!I
MGP*\"!JP'.,HH8T%8Q(RA._]N/P9,&FM5X64,\$E#89BW3#GN-5W7AD6#\87
M$!GEW:GQ#&O+3HOE+3T[##\^R=[8DMLYS8).IF(M>05TK*B/\.M,DP#HG%%>
M* 6KC68#A\EC%'S8 Y?R 5KXK;J*W5<D].)3"6T@L-5)](1&,80)"L2_C!9B
M7X2]_:VPI!&/QGWL_&[TH'_OC./WEE>B'_2^FO-CT1=X=-8T\O1!BEHK'O;^
MRPF+-9O\R-%8\>2SP:0<O(%;2AZY=>)P:?EA6;/CO9NFJ:]PSLM_D/.?K7/-
M-;=,7I+VH_\W5_DMC)/Q]%P<T:L#.EL)7(0;^A7N5WGF0/:=D$[H43N*LN3Z
MQ3GUX1W;^PO\*KY?7_**==+M9G!#S_(77HI.Y?.J>ZC+N.HL?X;[:)'-M[#/
M)73)>UYN1]76^T$D7O!9QP<<GB-WPQ-',)^ Q1' L#P8 \PG>&%Y_J?]K-#]
M! SCMHHB*]1GA?H$KQBR'3Y8GKA/[I_X3O,\3;,,J^AV&V6PQ>J69? 7CX9Q
M P\L#V1Z6ZWQ;N,3\OH<8#U];4*PG>*3B.T4KS4@\;J!1Y['NXWE 0^L"]CL
M0/YX'IBIN$^:0E<Q;M@)QI$\QQ"8Q?B,9AE2G0P^\?Y@IR1-\SR. !9GD*88
M J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$%     @ P8J&4Y>*NQS
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M"Q4&L&]R( DNR94;4EWI>::W=Y-[2:AU[D&P]_ :C1W-CQ^W_ %02P,$%
M  @ P8J&4R0>FZ*M    ^ $  !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN
M<F5L<[61/0Z#, R%KQ+E #50J4,%3%U8*RX0!?,C$A+%K@JW+X4!D#IT8;*>
M+7_OR4Z?:!1W;J"V\R1&:P;*9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2
M*+I!V#-DGNZ9HIP\_D-T==UI?#C]LCCP#S"\7>BI160I2A4:Y$S":+8VP5+B
MRTR6HJ@R&8HJEG!:(.+)(&UI5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#
M!!0    ( ,&*AE-ED'F2&0$  ,\#   3    6T-O;G1E;G1?5'EP97-=+GAM
M;*V334[#,!"%KQ)E6R4N+%B@IAM@"UUP 6-/&JO^DV=:TMLS3MI*H!(5A4VL
M>-Z\SYZ7K-Z/$;#HG?78E!U1?!0"50=.8ATB>*ZT(3E)_)JV(DJUDUL0]\OE
M@U#!$WBJ*'N4Z]4SM')OJ7CI>1M-\$V9P&)9/(W"S&I*&:,U2A+7Q<'K'Y3J
M1*BY<]!@9R(N6%"*JX1<^1UPZGL[0$I&0[&1B5ZE8Y7HK4 Z6L!ZVN+*&4/;
M&@4ZJ+WCEAIC JFQ R!GZ]%T,4TFGC",S[O9_,%F"LC*30H1.;$$?\>=(\G=
M560C2&2FKW@ALO7L^T%.6X.^D<WC_0QI-^2!8ECFS_A[QA?_&\[Q$<+NOS^Q
MO-9.&G_FB^$_7G\!4$L! A0#%     @ P8J&4P=!36*!    L0   !
M         ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #!BH93
MABTIH^T    K @  $0              @ &O    9&]C4')O<',O8V]R92YX
M;6Q02P$"% ,4    " #!BH93F5R<(Q &  "<)P  $P              @ '+
M 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( ,&*AE,E_Z>A1P0
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M2P$"% ,4    " #!BH93)!Z;HJT   #X 0  &@              @ &Z$0
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #!BH9399!Y
MDAD!  #/ P  $P              @ &?$@  6T-O;G1E;G1?5'EP97-=+GAM
7;%!+!08     "0 ) #X"  #I$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d257552d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com//20211201/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="d257552d8k.htm">d257552d8k.htm</File>
    <File>d257552dex11.htm</File>
    <File>d257552dex51.htm</File>
    <File>d257552dex991.htm</File>
    <File>meip-20211201.xsd</File>
    <File>meip-20211201_lab.xml</File>
    <File>meip-20211201_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d257552d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d257552d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "meip-20211201_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "meip-20211201_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "meip-20211201.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "meip",
   "nsuri": "http://www.meipharma.com/20211201",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d257552d8k.htm",
      "contextRef": "duration_2021-12-01_to_2021-12-01",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.meipharma.com//20211201/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d257552d8k.htm",
      "contextRef": "duration_2021-12-01_to_2021-12-01",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.meipharma.com//20211201/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.meipharma.com//20211201/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.meipharma.com//20211201/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.meipharma.com//20211201/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.meipharma.com//20211201/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.meipharma.com//20211201/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.meipharma.com//20211201/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.meipharma.com//20211201/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.meipharma.com//20211201/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.meipharma.com//20211201/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.meipharma.com//20211201/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.meipharma.com//20211201/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.meipharma.com//20211201/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.meipharma.com//20211201/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.meipharma.com//20211201/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.meipharma.com//20211201/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.meipharma.com//20211201/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.meipharma.com//20211201/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.meipharma.com//20211201/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.meipharma.com//20211201/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.meipharma.com//20211201/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.meipharma.com//20211201/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.meipharma.com//20211201/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001193125-21-349142-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-21-349142-xbrl.zip
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MJI6E"N6-6+H$"5\R_XRT:@OXEMS"#D'C@FJD)GMW22-*]-MZ#I RGI>DR)+
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M7?W/^+:C(WC5BWE5U7>TST<_?Y%]_C.?SYOD!3P)]CR?K.  PXE*OXC&!1,
MWM^TR8,']10DKL[S]K/OZ\,[WM?#SW]OO@0]!;_)RFGR&^CK>;[(RU]NI),_
MZ<X 0^:T;.MJNIJT5;T^0+LEZ5I8:9(ES_-Y=@568*+*I  ENX>7R[_]KZ.'
M/SZ&!XG&P4?@[WYZO)\FR[I:5@V\LZV2HFE )^",&Q!H_ U^O>&[:3Q:V<NI
MS!:@K8HR 3/KW>0BGZ[F>7*,EE7GI?9*,V^&UR39^7F=GX/:PVO06+.-LV:+
MMH'YD$7;H$4+X\WJY#*;PSC_]^'!(?_O?K+,:_Y6Y^5L%YO7'B3OX>]]RQGF
M>@93K>;3Y&Q-TY;%2N#/X]$DF\]ANL&S7Q3U(O$O.. WP'XDV71:X/*GP8,N
MLB8YK[,2M;PL;7#=PX)42]HU^.MR54_@"WFR6N*/F7\H6 GWTQ_N/[*CAR?#
M/EX64]X24$'X2;YM[O.4-WU]</+C$8RC6<&8\3/-:G*A0V1!@T69H!TS7R>Q
M%7J]E#?V5PF'9!80A2Y-BAD)GRP.G!HX,<%;BP9^F]>3HLFGO+B=5^PX+C1Y
MX)?]83EK:#Q"W;WGON+^$!R>#?=[$K_>_1/YN^&)F&Z\2?QWS:?L RZR2]AH
M.%,L8=FD1<FHXR9G$S,Y]XIR/*(5GV3+;%*TZS1<NH[]:M\.@C>IRI)E+[DJ
MX(K KU:T<.4YZY5LGNL PET *0VV'?X)6XG;6596> ,E-"\:7-0JHH5XW/"I
MA0R^,W+9<%B?%0C3>(2O@QF $@'-M\CAP*VK58I_MPN4LH"&3[8?D,>:Q^0%
M3H67')9A-0<%5O'/R_D*=H!>@C_"ZN%5 1OVSU5!2_+%;YOW'7T%2P8*%Y88
MISTK\"2YC?7B27\]^0@*JSRG[R_@)HE>/_*'0.IAL?+Y#&9]#KO)]Q;((&P3
MWK@M;>Z+U^"U:P#H A;Z7@/2F?]25E=UMOSNR8NJ7O#9>W?O0?KK]_CY)Z!?
M0!BV?O=5=<!???#@P;W[#WXZ?/2#>T)13N:K*0EO<H;:&+1LLP0)7S6=N3W%
MO[YQ?[439.V*4C9T1):KLWDQ&8]V/BKO\(3:!4O<>I$TP=T, H :U4T 'S,K
MRJR<%'"*W,=!HG..9/$N-G*(&CZ ;87/X"_#&N._80WAY44+DYK >Q)4C*1L
M^6AV1>,8E!#>[C\_>! .30[2>%33Z_!'F!$<#YP/W6>+U?R<E"8-A9^^9Y5[
M1S>%;PT4M=E(.)?3:K*BR>/OO6Z&4SG-\P4K3]BRX(]P,=8Y[D(YR7E L!8X
M:#PJ18FKPSOA'H%!SC<8R$Q^70Y8Q[WCF]CS^M.R_>X)RZ8\"1_Y_/2_G_SZ
MO41&X>'T?_"&IEW/\U!%Y(N>AL!?+;/S_-Y9G6<?[IWE,/#\EVQ^E:T;#*'^
M^H^WR;O3_P^&^N [?21%9G_Y7S_3_[Y+_CQ]_OX?__X=6.'_QT6XGIV\>G_R
M]F\7MH6'PSYF:#3*C0*BF+6LP.&S*)E.?LN\:1)K[[P%P>3E?_C@\!C% _[[
M=%#,4S1/8N;&6WM0W^G)LV;'<;D>.,[C$6O=CE':'6;R\(?[>V?[PT=PT^6\
M1=T,3LN\=WB*J5ZT>(' F>8S,VMEF%.T_DD5R'; =/&85K/Q""=*MLCV-_4O
M^]BG@LN950*=Y1U>P$8T7(?S8@%:M%[;JZ!9+9=S'L>4E,6KZM)$>A\<2JAW
MFC>3&G2MJ./.,CN%Z*X!E=CPJGEC!N%O'+@3=!"!YFNK\YP,$+?GG:MJ4&SC
M[^GN*7YE8$2J'2MZ?WR]Q-;',8U'YKL@KW:QZ?)I+^#HRAKR!36PA$EO!?$/
M!9MZ\-P"[:]*KD01-YF(O][AKIKF<&/BX<OGU=5UUS+S*QD7&Z, QJ-C&1Q?
M+#WCE;:C;UQ8.U,O^/GVE;;S_(1%#<7R!;W[F@(Y'L57T9@<LZ)N6EX<48*!
MQP+3 L4V0U<255@3UV$P/LI"P<;WG[W(0 UDEUDQS\Y #\1\\X[ZA8\L,,R&
MEGK>M/12]=CK_B62'/WXP*OF\2C4S0>@<L2P:&3_=0SQ@Y72J1K01?Y,>B$@
M(2'KA2R;2LW.J)SH [J",H&Y5R5933!;TLO^ 0=)5X"=7!S#DXL)KNQXA/>S
MD5XX+(]^.3Q,E@>+@V3/Q?>>@=M)]\$^&O_1K-F&]\W _4UPWU!4E[%#<R'^
M%AX;_% #.PGB *L"*\]7P>&C#=<\KI![W7NYM][A_1D[H^,1OJ?9O)_.+D8K
MPV\&N@P+L"8+N%7FZU!S^75-< PQ[32P%!A/H% +&- %^HG%K.C'\IY2+(^=
M -"&>A<//#.U^NX%?&8\^E,^%/6*O"-M;6>_$QV7_ID93'_O?^7'PK5?97CB
MJRM^"\5*>?5U=#5^HG&?"-2\V_T'#P9W?Q_.$;HHJ :K4"VRXAF/.NJ3O/K%
M<DZ& 8Z8= DHW<*/"M>SS4L*=:Y*V%4*WVT8X0;YW-]P-G[/Z@\Y#?YW&$X-
MGJ ]%[)2L-,+_6M""M-OD(LR8K2XO 3=5Y%V3.&#XY$3O&R)'X3KH)J%,= !
M,W3AQB7:N[.H'6T>^'-H.L.FXI[R:'E4B8_VH#M).KXSZ&!D>U<7?'K0\@ E
M#L.#A^3H:]85;LE\OMZ_@XC,L:INOA_H]@+).<8HG[W7XV9K>L-K)(U= 6B1
M#UPNUIB^+>\:Y'B'N<=B&IU(!OY4R=YZ4>8X!@88^7C@.<WPE*6JM_GW,K6I
M'!*8!O^>7J>_Q5/F_D+>9C63/VW;G.V^QZUN(O]RX-:2P*2UQ%E1XQ[S$IK]
M@._/BP^PDV 8U#!*%@786K_/9)F2\2T"@I_@>^33]JU@U=3L*E-B]6W;B/'H
M[[4372N!PL3XF$6VA@GO=D3(M. %#JR+1G3'>/3WF^U.PA0Z<#@@U3WQV]&%
MJ#DH.1X=_?S@830JF=Q:4-*^,X@*BPEPVU*\8;O&HVOMURU*X!>ZH*)#QGEO
M/ $4HIBI4YB?5R!/-'O\PZ"Y&]Y[^-%)M5P[W[B3*S$Y$>L<8M3]Q)D8R?.L
MS9+?,GP&C>$8/.IU4[ <OLW;NLC1J'JW;F#Q3#KPY/EOQV^#)/<M1YX_.ZY6
M89OWDV^1[MNQ&T]95>27'!V5H+?-[54EN)3@T<-Y.&L*\#%KUEUEDH5'VL4D
MU"1R7RA<'E4.D#X_HKU=_(&N?TR%SL-7@[^W6*&]WI"S)S^64_[YX": G]O*
MA7)Z^&RMH::&3FZF*J[Q!SU$=#3PAOF\NFI^^=31_WP#W)# 0 CI_/2)_$?"
M*(PCZB3TJY)5S9]9C3@5@D'(U\+]E5\>R'\IM/;>BA>OED,>@+Z\XF?R"R85
MB&4F^C?/0![,NM$U(^^;"C@HO%+L)UY0"._9O$*)0@V:D\?,,LMY!O&>&6#!
MWZ1W,G:D]UW% H1?]B&36]S5FZ#!]K)]W;M?3PG2-2\R- Y(!H-;]BT#"4A$
M?_W^](G=ML3N%P8S&X[%UN8[>!]B) %7#%/LVY/I[^X]T-SY8"H*QUFM,'@J
M X>1_I:7!$8Y+6'P*XX.G!X\/?CA6J\^T'>?X/:*@ PDC"0Y86P#S7B3<CS+
M)]5.R>V#Y%6%V+0E6 SXB68%)D+I4NYA=G'SD,3D6%9->\^_>&A\><EXO>F&
M2&59R:C@'.)%0)9RC0B?8)"RQ1NBRGW[O#L(7$]X'7QGDN?X9)8>9UQ5B)Y8
MU8PU)* 2?QLVO&A7$B! ;UP'5M6IFHXBIGC5_/"X23[ EH-U=9ZG07#M(!!I
M'-^$#H?:87CFQR,)V2=[?)SW.2G9L=%HY!YS9-S/@VO(UM:=3(-<= 12D?HI
M%'PM:V0.3@_MA+EZ@I/KZ@I4(,8C/'OJWG2.Y%OOX\@$-UG=D12?GUI@7\<G
M2LKW"M7HD)'\=YLWW )SV(YZ +FI:C(:W40?S^)Z.BN(ZU!AS)[M)8['3S*'
MO@TCD D(6]DL,%J,M^BR4*!.S^6@^H*8ST'. J)^)OG2.6<"NEOFM3P;;F^_
M.+LHW_=.^;Z_C1C@1D\WLHY@8*#E"K]<(^:C@TS"XVP$$#^57"&^$/Z J\=7
M/6J?7402WT[[1;]9WU!$@V#$YK"#-[YT0[W*MX\9C\*4;/ *(^M]5_$+FS!G
MUH1Y7C03,,%6==ZS45X9\.2 *)1\R43N<5(Z:*=[.6@I42:B$+$<64Y0H45L
M0[YM.$2L__1G5WZ!2.U5"39,GA@((UPU7CQFB,N%KU5\U%+ZAW\0_D1N4DO0
MF,[W1)+D  E.<JHA<WP(J!\P-5!_8<@L^\!A,A-DU<^659N /,WS#.];RAJ)
MH/53BQM"=]-B2H_RH9#K+,#P3/T\:%Y3=AYU0@8AZF;D< -SK+?4R4R*&G01
M?)I\63XX'$/V:@"S0VEO0:STF0F+Q&V[\Q!+;9-4YC9!G0FJ=E_]&-Q^KKV8
MDIQU$&H4A^(PI\=,#&AWSB;<?PA'[!,$77,>[E]>/&^VS=>6\^CNCT<;Y/FV
M=__S7V.;SY6#@P71S/ 6&U**L0N0[D>*O0S,*A@X+<R&R[ ?"98;&"[3:02*
MT,_C;%\:QHO<.#F2.M7D+NS/H:="C9Q\FD(&">^(8!V)SURY^(P+MV,@3>Q.
MCKW1O)=HGNC(=<ME2K21C7=_!D1IKZ?M1+_M7S>CTW]2H#=)K=&#.5E?E#Y"
ML%I6FOFA$%R%9NJ:I4NQ$U:V9JNZ+)H+;ZZK5P@RCO\QUCO\N:Y6YQ>R!F&I
M3/X1?V[F:V?BMYJ;?H$0 _5G(Q$J$OIR'F+#F\H,36.DK,]#"#G#\?K%7#]C
M;I+M_:\WR/_@6Y#_%FWIB;6E$7F5](%7>?,X<=BHOI5=)?9[ 0X73QO8@FU@
MZ-)OO&ZWHNM,Y"T>7$2#A^:2R^1NQ8FD/MYBG'=4<FT'=QQ<VIVJ $R1C$<8
M-4+-2;$IT$W@W>>"REM44\;)G;#G/),I#"[YSB [GH!W]!,'4C//"%3:NEHE
M+.L>'MLO-L6): %7RHBP2@ <?%^E[F8<C^##J0O-PO-K01MZ:%K9D&*3)Z8<
M-:Q=7B?=E"^5Z(J303$6\*&P.#R:KLDP<+.X:]UF 7H>BW?'UENN^?'HNO[(
MYFO\MNW0NZ@XWYMV'/06KJ,5'6&8SVL-9RF(,'D:8.EZ"N:-Q:UBK+;&Q^P5
M^WS[< !J68B2P(]B'*J44D"%!+*CTJF@CE:Q]DJ@6=#W"OM&"M[D.J=N3(]C
MS2!JX=3Q8SUD>4J3C)T^]W4;-0K_(!%R65$G<EB'^PG5M*+[0*G=V 'IQ7K%
M?!O0=W<DJ+D55+C(G$@>3R]1>2?/* +6$TE1XIFLU%71=$WW%'/4?,MH1 \]
M*?30&]$\=(#'H\"K:9)SS/9\BN<7N1OWCKWD@J9PR9>R\B*3R8PEYB<# "%2
M,@(/N=/+$:>=)KXHXFP%<\9$53:;97"QX)_<[U2;J])U##9LF;=-8G$!5K<3
MV #..)I1<*LT["N2A*)_A)X*_!;E2<8!#C_?XA.XB#@YY8:QEUD\\\!N&YSY
MWM/]1%=-LTZP;!1(SR;L5-'(Z'9&VR $!OLD5H$Y4CO'-#QF59/O,('4($_=
MWM'Y%BGK^BPW6%W2=L\&169:((B[Y$!&1\/A&S_ B01C:3)GRV&9%5-0PS7[
M9=WEX3L6/MMXQHYL6;2$[*PF'^XFPCRS>N$4'H1I1;S[CR>P)6 ;#*7$,_]W
MV*@*M'!>B^V&TQZ&K8(C6]6D%#V"5>-HMQ '"GY5HZ#Y.7']>#!TXGV0P(3L
M6#<YW/^=S1&D[);:%$+:SUN8+_B!\FADH7%!7N/A)&OH:975T[N1B// 3])M
M'(_<-L3E(;KA;E])=7Z^X%]X'?<L9"I%R;N0:="GJ)HDDI&@(I^O0^$=CY95
M4UBCIJML4+]4\X++60/-(R%(O@=A0[!:1<R;P"#&)U?@0(DXL3*XJ.93;UVA
M@+;\SDG67"0S!-5<?T3JB<'+BFH*BA)6C$[L8["0BJF=MME#?QLXDHM(=.F/
M@W<'R3FC4V 5X8B!V8#3]=(-.A>>OL3E]Y#,WXZ/WP0L%TO.':*Z9.7=4,;U
M+$-\I\2@T/6R$RG*RVI^J<B&F(;Q_F%GN]'U@2'64W0XI#('Q]1SV#>&+^7%
MY)KF9B%Q]S._Y:O%@HITW9_#..]GT8$1\0XB;>!DEA)2%*(&O^%H^E-HFW:#
MM\#LB9ROS#EOV0I,J&#^,5W@ULS;EMV_$2+GHL "),KQ4YE21;6H6?SI$B+M
MW2QX!72VSB@EM$D_@U;JQW2'*3^BOPWP%@@<G[K<;[-KZ*@_Q%LGVOABD="'
MWR*A-R;VV.PP;;R8W6E$]KF:0HY;$2ZLV<NJO,>JG;$N_LPN\HS$V%1M4K*-
MBO@+PR7 NHJ 'EQ0MQ'IL:\@$T5W*B3GMT$<R2D6!QP=XM^O!^'Y3YU5#T0E
MUE^ %<I<R(UOB0)%(W-.<H:G./^_\-&FP+#<4W%_L-A(U=E+&/<J._^\"53[
M*[DL%)7<CUXS=<.,/>(XJ(>ODJ9O.OC[-@K"4O2BA_B<KPK$E97XHX]?MEKE
M?!=&\D4<F ,"B1R4<Q[W&\1X3E'8'R?/0:PG!6R5)"/Q[F$GG+#=IR@4"*&4
M!Y KD#CK.W&RL!&>3.%Q@5WV/.$%W!D4ZO79[D+?.I&W5OA6?U9K)X&VN)KO
M,@)0;#TL1P_N94>/]+S@^/@KX$YL^-*CZ3W_I3B$RUZ1 EA/&J[WP<GKQ(SY
M.=&M:58SW@N*($BE-N;CFZHDR0(/?55S )JL&Q]4LK$0M"SRCW#TV[A8@ZS
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M,MI_&&[5-2.[*7N.A"XKBI:0$IQ@PUGQU2E;Y<JJT5U#[V,*O@#5D* *QX
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M[9D6J^.MJ6/%BBD/M!HD;_GNC:YKE/:EERN5QB;X369"T\7@JY 7PV4LC/9
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M84F'N&VXCZC0V^PCS+%=U64L/Q_SJ.5./B.DF%S-W$W6DXSQS^H]MCBHI+E
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M6E=VQ#WCA=9N@.D_78$<K/6%F)LX]OPWI^7DP%*FG;YZ>QRD@VX9XQXIC!J
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M^4DWE7FV8PU#ER ^,BT_$$?XZB\IFXAC2Z?%7#*X#<3@["YX*HNV,Y2T(*M
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MLR^[1<G..]0/6S].X+*G D(LSQ^/+JJK7$HMI27W<C=[?]-J?RGC^OJ&1,R
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MZQ_S\6W0(JZ$AN,LNX8#* GE1_<[[5J:O,ROBH87_-^RQ?)Q\K2:?"C %Z"
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M5,?N7K:P=TB!&-J.Q!I>!JI<Q!D?/6!$D1YF4$FELH=CDC8+L4KK:(.WV1C
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M3U-M<R2&=J"!!"D35]UJ4]@(+4)'% "/ABJ()&]E6.$Y2!POG >:8<3!XZ_
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M3>!\R3;:S)1[=FLH^/.C3_C1_3N7_P!02P,$%     @ P8J&4^WM'21* P
M?0L  !$   !M96EP+3(P,C$Q,C Q+GAS9+U6VV[;.!!]+]!_F.II"U2BY" M
M(L0ILIL&")"FA9L6^U;0TM@FEB)5DDKBO^^0DFS9B;VY+-: 8(HS9^9P;M3Q
MQ[M*P@T:*[0:1UF21H"JT*50\W'4V)C;0HCHX\GK5\=OXAC.SB^N((:%<[7-
M&;N]O4W*F5!6R\:1!9L4NF(0Q[W^7]??X4=K/8<)2N06H>+6H8$_&R'+?)2.
MLO3]*$M&0YA![NU!R1WFD(W8!^85X2#/LCP]A-//\"E847 M*AQ"=;TT8KYP
M\$?Q%@+H3"N%4N(2SH7BJA!<PK>>\3NX4$4"IU+"Q,,LT;1H;K!,.JMWMLQM
ML<"*OWX%0/%2-E=DLJG&D0]$%X>[J9&)-G-6.L/<LD9&2C%IH1%%-(#^.^X>
MAA+A)78%G'$[#:!>XL.3QFD6'V0#7(6BWG#F-Q;<5#PDRD<G&Z5#1(EB!0C,
M+!;)7-\P$CSLPVN)AT\T2M,#1M7A*.@X@$BA_MF#\.(I%<K0R3W([4$ 9$='
M1RQ(MRB5;O,<G?5#U@J#MG^X<T9,&X?GVE1G...-)&2C?C5<BIG ,FA2Y5:H
MW(;.IH;C9H[NBE=H:U[@TZ).)?;0X8AOQO[^?/DM5%]TX@$ H2!%56OCH*W+
M2UV$=MD34_\6]ZF(_5:<C2B1"1F+0#U(>T<>@;V82)_A9Q%9E<>CB=A=Q>P7
M\;JJ=W'8UPC/CL9VN_M8'/E89.\?%8M[X^(_8*+5U4O)#&;>BM SLZ2X*/Q@
MRSZTR]@OGY"I-?ZEN1H,#A^9P[WNMR=-YS7XY$II%QP-F?"Z%FJFNRW:]"6>
M]W4^P1F$"9=S4Q@M<?\<9+71-1HGZ%)8MTIK8&%P-H[\.(K[*?13\FE"4ZA7
MN>=@L_F\F!$$Y>6:7H]UPGGPI1>#E]/MRN7*M"^0<60I[G+0O/_S<6N#3STN
M02P-_Y"VW:?^.M!Z\N&]GVO2 +_X/KG8<WVL[@_F^)U6NEJV+,]TT?@[JO\_
M5>4G1=R6%U1:!/:\(A!TT4Q(_>>CU%<L>YXETM>>"/6;I?Y''X.]A>&2JQ):
M<S"P=\RVC6S;;RR67]1)6!=<%HU<1;T#=QK[@-OY>CQRS6PWKMOM,];W,=MN
MY&YGV/#M5CMPZ/4W4$L#!!0    ( ,&*AE/<'WQY?P8  $E'   5    ;65I
M<"TR,#(Q,3(P,5]L86(N>&ULS9QM;]LV$,??%^AWN'EO-J"R+0?H4*-ID3G)
M$"Q/2-QMV# 4LL38Q"32(.78_O8C]=#(,253T:G*B[:J=/>_^RN_4QA)SL?/
MFRB$1R(DY>RXY_:'/2#,YP%E\^/>2CJ>]"GM@8P]%G@A9^2XMR6R]_G3VS<?
M?W <.#V_N 8'%G&\E./!8+U>]X,'RB0/5[&2E'V?1P-PG#Q^,OT"?Z3EQG!'
M0N)) I$G8R+@UQ4-@_%H.'*'[T=N?U1,$\33>A!X,1F#.QK\,M"!<#1VW?'P
M/9Q<P5FBPF!*(U),Y<NMH/-%##_Y/T.2=,H9(V%(MG!.F<=\ZH5PGW?\#BZ8
MWX>3,(0[G295FY*(1Q+T,]60LO_&^J^9;A[>O@%09Y')9-]Q3Y^+[%1L9B+L
M<S%7O0Z/!GE*[RECLY>R/DH2W \?/@R2H\5H24VQ2MP=_'5U>>\O2.0YZNRK
MKY:?E9%T+)/]E]Q/3J%%@U :H?_GY&&.WN6X(^?([6]DT/ND"V9GQYN1\%)M
M0>)A+'A(*@KKPTGU7A8?;Y<JGFQBP@*2*7_3YGX6M1#D(575["62DOC].7\<
M!(1J0(9ZP]$;SM#-^OQ1[?HZX0KZDYF,A>?'NU5#?:*XR'<F5HY[AJ3!;ELZ
M[D3X.UJ>\',=M7G@+&01 Y^KK]XR=A+%//U!\,C815:.&PY^#6>AL4W-D]K2
M,TZ8\^7^D-=4J&A,$,E70D%6YPN<^/F4*,,_N?:_'P=/M5]+J^I"(LEEW7XQ
MP#R)%/+J3WP>>G-;,)\E=02FN75N.-@$3(,0$IC?E$%+-\:RA4:+6-IVBP'E
M&8MIO)VH8L(++]0E>?,[V=K"69+<$:355GA%4!-H*P21X$TK0%8"DAJ@BC3&
MN,76BSC7[Q\#[%/NK_0,394'6YYW<SK"V-@XWS_6!-I]'216<V'0RHT!Q6^S
MR*5EKY@PWA)!>7#&@E/UPTY=*I\E=XRGV0JO",( UB"(36Y: E0-T$70(&ZA
M=2/-UOWC+1_NR)SJ)32+K[W(FFMS;J>+AQ(CO#RF^=+!I(>[<GBJ +H$TKJA
MC;X-RP;KYO%POF ^%TLNDILJ][$:H@E?J<7+=L*#FG0?D.H4=CN;W#JE^2A8
MR.-.QDY!2"I"5A)T3:11^0Z^#)/S<G-XHW1.0W*]BF9$U)N;8EZG0V(PP,W'
MF^/_7 N7=:T.J3P2UMC]&ABV:AH/UZFWN0C4(HH^T/26^DO8+17I%.1#UKA%
M<'/$*X5Q>5>E8+<6+OVM6C&,P@O\X W&21 H&S+[YY(RXM8;"J- IP-198D?
M"&P^"*6BN$.0Z;_+-T!7@AN&M;)IS89A %[@I<T!&#4=@-&K&X"1[0",VAB
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M.R[5EOX5,-DNFOXB%+7G?U!+ P04    " #!BH93-]?&0<0$  #1+   %0
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M0YG"P2/RHO8M%I0$L,Q!))#8,*8#WZK+EVNNF\$KXU(*[.E;0-,0-Z;R*4B
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M-3<U-3)D97@Q,2YH=&U02P$"% ,4    " #!BH93-NX,T@4(   K&   $
M            @ $%O   9#(U-S4U,F1E>#4Q+FAT;5!+ 0(4 Q0    ( ,&*
MAE/P%.PL5PP  .XB   1              "  3C$  !D,C4W-34R9&5X.3DQ
M+FAT;5!+ 0(4 Q0    ( ,&*AE/M[1TD2@,  'T+   1              "
M ;[0  !M96EP+3(P,C$Q,C Q+GAS9%!+ 0(4 Q0    ( ,&*AE/<'WQY?P8
M $E'   5              "  3?4  !M96EP+3(P,C$Q,C Q7VQA8BYX;6Q0
M2P$"% ,4    " #!BH93-]?&0<0$  #1+   %0              @ 'IV@
K;65I<"TR,#(Q,3(P,5]P<F4N>&UL4$L%!@     '  < O $  .#?      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
